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DISRUPTION OF THE DISCRIMINATIVE STIMULUS EFFECTS OF
(+)-3, 4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)
BY (±)-MDMA NEUROTOXICITY:
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Thomas B. Virden HI, Ph.D.
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It is well established that repeated, high doses of 3, 4-methylenedioxymethamphetamine (MDMA) result in the long-term depletion of serotonin levels and
destruction of serotonergic terminals in various locations in the brains of a variety of
species. Further, it is also well known that concomitant injections of the serotonin
reuptake inhibitor, fluoxetine, prevents this deterioration. It has recently been noted
that such MDMA neurotoxicity disrupts stimulus control in rats trained to discriminate
MDMA from saline in a drug discrimination procedure (Schechter, 1991a).
In order to extend Schechter's findings to the optical isomers of MDMA and to
explore the potential of fluoxetine for the prevention of the disruption of the isomers'
discriminative stimulus control by neurotoxicity, rats were trained to discriminate
either (+)-MDMA or (-)-MDMA in a two-lever water reinforced operant procedure.
Most of the rats administered (-)-MDMA died during the neurotoxic administration,
obviating any conclusions thereof. However, the stimulus control by (+)-MDMA was
maintained in rats administered concomitant injections of fluoxetine and the neurotoxic
dose o f (±)-MDMA, but disrupted in those that received (±)-MDMA with
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concomitant saline injections. Control by (+)-MDMA was reestablished in these latter
rats with subsequent training sessions. Postmortem neurochemical analysis verified
the neurotoxic effects of the (±)-MDMA injection regimen in that serotonin and its
major metabolite 5-HIAA were significantly diminished in the prefrontal cortices in
rats given (+)-MDMA relative to control. Conversely, serotonin levels in rats
administered concomtitant (±)-MDMA and fluoxetine injections were unaffected
relative to control, indicating pharmacological protection against MDMA
neurotoxicity.
The deaths of the (-)-MDMA rats are discussed in light of the predominant
environmental variables, and it is suggested that elevated temperatures during (±)MDMA treatment may have contributed to their mortality. However, the results from
the surviving rats indicate that the discriminative stimulus control of (+)-MDMA as
disrupted by (±)-MDMA neurotoxicity can be established, regained, and protected
against. Although there appears to be a relative paucity in research regarding the
behavioral consequences MDMA neurotoxicity, the present findings shed new light on
the potential use of fluoxetine as a tool for such explorations.
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CHAPTER I

INTRODUCTION
The ring-substituted phenylisopropylamine 3, 4-methylenedioxy
methamphetamine (MDMA, "Ecstasy") is a drug that is as singular as it is popular.
Although it is an amphetamine derivative, MDMA's subjective and discriminative
properties do not altogether mimic its parent drug. At high doses, this compound
produces neurotoxic effects on the serotonergic system (Stone, Johnson, Hanson &
Gibb, 1988). However, little is known as to the consequential behavioral effects of
MDMA neurotoxicity. The present paper will attempt to shed light on this compound
by focusing on its discriminative stimulus effects through a series of channels. First, a
brief overview of the drug discrimination paradigm, via a short discussion of the use
of drugs as discriminative stimuli, the history and general methods of the drug
discrimination procedure, and a synopsis of the limitations inherent in such a paradigm
will be provided. The paper will then outline the history of MDMA and discuss
designer drugs in general. The subjective and behavioral effects of this enigmatic drug
as well as the effects of MDMA as a discriminative stimulus will then be considered,
followed by a treatment of its physiological and neurotoxic effects. The present paper
will conclude with a description of an experimental study that has provided new
information regarding the effects of the neurotoxic properties of MDMA and the
protection thereof on the discriminative stimulus properties of the (+) enantiomer of
this drug.

1
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2

An Overview of the Drug Discrimination Procedure

Drugs as Discriminative Stimuli

The discriminative stimulus is widely considered a mainstay of the analysis of
behavior and, as it is a primary component of the drug discrimination procedure, it
seems necessary to briefly define and discuss the terms with which drugs may serve as
discriminative stimuli. Michael (1982) offered a definition of the discriminative
stimulus that requires the discriminative stimulus to increase the frequency of a given
response by virtue of the correlation of the would-be discriminative stimulus with an
increase in the probability with which that response has been followed by an effective
reinforcer. Thus, to be established as a discriminative stimulus, a drug must produce
subjective effects that are detectable and suitable conditions of differential
reinforcement must be arranged in the drug's presence. Various drugs have been
established as discriminative stimuli in many species (e.g., human, rat, gerbil, pigeon,
mouse, cat, dog). For the most part, no general difference in drug discriminability has
been found among these species (Lai, 1977).
Most psychoctive drugs and almost all drugs of abuse appear to exhibit
discriminative control (DMello & Stolerman, 1978). These drugs seem to control
behavior as discriminative stimuli as effectively as other, more conventional,
discriminative stimuli—such as visual stimuli or even electric shock (Overton, 1964;
Harris & Balster, 1971). Further, the speed of acquisition of behavior under control of
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a drug as a discriminative stimulus is not significantly different from the speed of
acquisition of responses controlled by other modes of discriminative stimuli (Overton,
1988). A rather long list of drugs established as discriminative stimuli includes:
sedative-hypnotics, anesthetics, anxiolytics, muscarinic and nicotinic cholinergic
agonists, narcotic analgesics, cholinergic agonists, dopamine receptor agonists,
psychotomimetics, amphetamines, antidepressants, and—to a lesser extentpsychotropic drugs. Some drugs, however, such as nicotine blockers, lithium, and
salicylates, however, appear to exhibit little or no discriminative stimulus properties
(Lai, 1977; Colpaert, 1977; Seiden & Dykstra, 1977; Overton, 1988; Kamien, Bickel,
Hughes, Higgens, & Smith, 1993).
It is important to note that discriminable drugs acquire their effectiveness solely
by virtue of the history of differential reinforcement, and the maintenance of the drug's
discriminable properties rely on the continual application of differential reinforcement.
Thus, the acquisition of discriminative stimulus properties by a drug can be explained
in simple, well-established behavioral terms. No unique analyses are required.

The Drug Discrimination Procedure

During the genesis of the drug discrimination assay, the most common method
of establishing differential response patterns in laboratory animals involved mazerunning or similar measures (Overton, 1964). Typically, the subject was administered
a drug or vehicle and placed in the start box of an electrified maze with two or more
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goal boxes (e.g., a T-maze). Shock was then presented while the animal was allowed
to run freely until it reached the appropriate goal box, at which point the shock was
terminated. Drug administration conditions were generally alternated along with the
locations of the appropriate goal box. For example, a rat trained to discriminate
cocaine from saline would have been placed in a simple two-choice (right or left)
electrified T-maze with shock presented. If the rat was administered cocaine, the
shock would have been terminated when the rat enters the drug-appropriate (e.g., left)
goal box. Conversely, if the rat was administered drug vehicle, the shock would have
been terminated only when the rat entered the vehicle-appropriate (e.g., right) box.
Ten trials per day would typically have been conducted with each drug in a single 10
min training session. The T-maze was preferred at this point in the development of the
drug discrimination procedure, as the subjects quickly learned to appropriately and
consistently turn left or right within a few trials (Overton, 1964).
One of the first studies involving the discriminative stimulus effects of drugs
was performed by Culler, Coakely, Shurragar and Ades (1939), who demonstrated
that different responses could be brought under control of curare as a discriminative
stimulus. Conger (1951) later demonstrated that ethanol could acquire discriminative
control in rats trained to run down a telescopic tunnel. The first drug generalization
test was performed by Overton (1961). After discrimination training was completed,
other drugs were administered in lieu of the training drug. In general, drugs previously
reported to have similar effects to the training drug produced similar responses.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

5

A modification of the T-maze procedure was implemented by Kubena and Barry
(1969) who trained rats to differentially respond to drug states by their rates of
responding on a lever, rather than by their choice of which extended wing of a T-maze
to run . This was accomplished by reinforcing or punishing lever-pressing depending
on drug presentation. That is, if the rat were administered a drug, lever presses would
be followed by food presentation, however, the same lever press would be followed by
shock if the rat were administered vehicle. Kubena and Barry also used a two-choice
assay in which food presentation would follow a press on the appropriate lever,
depending on drug (e.g., left) or vehicle (e.g., right) administration. To test for
antecedent stimulus control, no food was delivered for the first 5 min of some
sessions.
Lever pressing appears to be a more sensitive response for study than mazerunning and is therefore more frequently used in current research. While the use of the
maze only allows for a schedule o f continuous reinforcement, a variety of
reinforcement schedules has been used with lever-pressing. The description of the
latter procedure most closely fits those most common in contemporary use. In
general, the procedures of drug discrimination studies currently used share five
common features: ( 1) subjects are trained to discriminate a given dose of a particular
drug from a vehicle; (2) the reinforced responses controlled by the presence or
absence o f a drug are operant in nature; (3) responses are mutually exclusive; (4)
these responses are similar in topography; and (5) the reinforcer presented for each
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appropriate response is consistent (Colpaert, 1987). The most common dependent
variable generally considered in such assays is the percentage of responding on the
drug-appropriate lever prior to the first reinforcer, as well as during the overall
session. Other measures, however, are also commonly considered, such as response
latency and response rate as compared to vehicle conditions. These measures are also
helpful in determining the maximum test dose.
In general, the criterion for successful drug-appropriate responding during
discrimination training is set a priori at 80%-90% correct responding for the first
reinforcer presentation, as well as the entire session (Colpaert, 1987). Discriminative
stimulus control is considered to be established after a predetermined number of
consecutive successful sessions (e.g., 9 or 10 out of 10).
Once discriminative stimulus control has been established, the generalizability of
the drug's control can be determined. As suggested earlier, this is simply performed by
administering a test drug in lieu of the training drug and measuring the percent correct
responding on the drug-appropriate lever. This allows the researcher to "compare" a
novel drug or the training drug at a novel dose to the training drug at a given dose and
the vehicle condition, thus indicating the subjective similarities--or lack thereof--of the
doses and/or compounds (Seiden & Dykstra, 1977). The discriminative stimulus
effects of drugs and their subjective properties seem to be well correlated. For
example, Callahan and Appel (1988) reported that in nonhumans trained to
discriminate the hallucinogen lysergic acid diethylamide (LSD) from vehicle,
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substitution occurred with psylocibin and mescaline, two drugs that are reported by
humans to be rather similar to LSD. Similarly, amphetamine produces cocaine-like
responding in rats trained to discriminate cocaine from saline, and vice versa (D'Mello
& Stolerman, 1977). When drugs exhibit this sort of reciprocal generalization, it is
often referred to as cross generalization.
When dose-response generalization gradients are constructed with this
method, the gradients yielded are similar to those found with other forms of stimuli
(e.g., tones or lights). As the test dose approaches the training dose, the
corresponding patterns of response become more similar (Colpaert, 1987). When
substitution tests are conducted with different drugs, the patterns of response tend to
be more similar when the neuropharmacological actions of the test drug are more
similar to those of the training drug (Colpaert, 1977, 1985, 1987; Lai, 1977; Overton,
1988). Such generalization tends to occur only with drugs of the same
pharmacological class. That is, although response patterns engendered by heroin may
generalize to morphine, they will not generalize to cocaine (Colpaert, 1987). As a
result, the substitution test of the drug discrimination procedure is often used as a
sensitive assay to establish the classification of novel drugs (Lai, 1977).
A putative antagonist can also be administered in conjunction with the training
drug to determine the degree to which the antagonist disrupts the stimulus control
maintained by the training drug. This procedure can yield information as to the
neuropharmacological actions by which the training drug produces its discriminable
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effects when the neuropharmacological actions of the antagonist are known. For
example, if a given antagonist is known to block the effects of a specific receptor and
discriminative control of the training drug deteriorates when these two drugs are co
administered, it is implied that that receptor in some manner modulates the
discriminable effects of the training drug. This interpretation, however, may be
confounded if the antagonist produces sensory effects of itself. The co-administration
of these drugs may produce subjective effects distinct from those produced by the
training drug alone, thus disrupting discriminative stimulus control regardless of the
presence or absence of pharmacological antagonism.
One primary use of the drug discrimination procedure is to determine the
relative discriminability of a given drug. Discriminability is often determined in one of
several ways. The sessions to criterion (STC) measure is determined simply by
calculating the number of sessions each rat was exposed to before the criterion for
discriminative control was met. Thus, STC is used as an indicator of the speed of
acquisition of discriminative stimulus control (Overton, 1982). Another method to
determine drug discriminability is by calculating the dose at which the drug produces
drug-appropriate responding in 50% of the subjects (ED50) (Seiden & Dykstra,
1977). Still another index of a drugs degree of discriminability is the asymptotic
accuracy engendered by the drug, or the relative frequency of correct responses after a
protracted training period (Overton, 1988).
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When the results of antagonism and substitution tests are considered in
conjunction with training data, a neuropharmacological profile of a given drug can be
created to describe the possible mechanisms by which the drug produces its
discriminable effects (Lai, 1977). Thus, the drug discrimination procedure has been
widely adopted in the field of behavioral neuroscience. In general, drug discrimination
procedures are used to address three issues: ( 1) which drugs have discriminative
stimulus properties; (2) which drugs produce generalization; and (3) which drugs
antagonize the discriminative stimulus effects of other drugs (Weissman, 1977).

Limitations to Drug Discrimination

Some debate has transpired with regard to the drug discrimination procedure
that merits discussion at this point. Testing may be performed either in extinction or
during multiple, reinforced trials. The use of reinforced trials has the advantage in that
it allows for the examination of possible effects of test treatments on overall response
rate. It is commonly held, however, that testing under extinction conditions is superior
in that reinforcement may provide new discriminative stimulus learning that may
confound the results of the procedure (Colpaert, 1987). Further, it has been suggested
that by reporting the initially selected operandum, the researcher may provide a better
indication of drug-induced discriminative stimulus control than by comparing overall
responding on both operandi. Comparing overall responses may be confounded by
tendencies to "probe" the correct operandum as extinction takes effect. To help settle
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this debate, D'Mello and Stolerman (1978) performed a series of experiments and
reported a high correlation between the initially selected lever and the percentage of
responding on that lever. Thus, there appears to be no advantage to limiting measures
to the comparison of the initially selected lever.
Although the drug discrimination procedure yields objective and readily
measurable quantification of possible subjective effects, the dependent variable must be
considered as a derived variable which is designed to accommodate some previously
determined theory or concept (Colpaert, 1987). The two measures most widely used
to describe drug discrimination are response selection and percentage of drug
appropriate responding. The latter measure, however, is frequently reported~in most
studies—with no report as to why that measure was chosen over the former. Further,
the percent of responses are commonly reported rather than the absolute number of
drug-appropriate responses. Colpaert (1987) asserted that this practice is merely an
attempt to compensate for possible drug effects on "total response output" (p 352).
The measurement of total response output involves the comparison of occurrence of
drug-appropriate responding as opposed to vehicle-appropriate responding and is
nominal in nature. According to Colpaert, this is the only measure of variation in
behavior that reflects the discriminative stimulus effects of drugs. Additionally, the
statistical analysis of such nominal data for each subject is easily done, but rarely
reported; as the total error rate is often 10% or less, response selection data can be
selected at probability levels of 0.1, 0.05 or less (Colpaert, 1987).
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When analyzing nominal data, percent generalization refers to the percentage of
animals that select the drug-appropriate lever. Otherwise, generalization refers to the
mean percentage of drug responding across all animals. When various doses of the
training drug—or other drugs—are administered in substitution tests, generalization
appears to proceed in an orderly manner from 0% to 100% drug-appropriate
responding as a function of dose. Typically, when drug-appropriate responding is at
or above 80%, it is considered "substitution" and when it occurs at or below 20%, it is
generally regarded as a complete lack of substitution. When percent responding
occurs between 20% and 80%, it is often interpreted as "partial substitution".
Colpaert (1987) asserts that it indicates either a ceiling level of drug effect or that
generalization occurred along a dose-response curve from 0% - 100% of the level of
drug effect. This outcome is rather ambiguous and difficult to interpret..
Saline appropriate responding in a generalization test is usually interpreted as
reflecting an absence of the training drug's discriminative stimulus effects. However,
Jarbe (1986) contends that although such responding may well indicate that the effects
induced by the current stimuli were dissimilar to those of the training drug, yet it yields
no information about the discriminative stimulus effects of the test compound. The
inherent nature of the procedure requires the subject to respond regardless of the
stimulus effects of the test compound—whether or not it is similar to either training
stimulus (Seiden & Dykstra, 1977). This difficulty has been somewhat compensated
for in the past via procedures in which a third choice had been made available (e.g.,
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White & Holtzman, 1983; France & Woods, 1985). In a procedure such as this, the
subject would be trained to respond on a third operandum with reinforcement
contingent on the administration of an additional training drug which is generally
dissimilar to the first.
Another considerable limitation of the drug discrimination procedure lies
within the time constraints of a given study. Each subject produces relatively little
information at a given session. Therefore, in order to gain data of any appreciable
magnitude, many sessions must be conducted within a given experiment over a
relatively extensive period of time. To help alleviate this problem, Harris, Wood, and
Lai (1987) proposed a method to shorten the time it takes to train rats to discriminate
a particular drug from its vehicle. This method involves one to three training sessions
per day (rather than the single daily sessions commonly in current use), with at least
one drug session with the provision that the drug sessions are only administered
following any vehicle sessions (e.g., W D/VD/D where V represents sessions during
which vehicle was administered and D represents administration of active drug) so that
no drug carryovers occurred during same-day training. However, Schechter (1988a)
reported that although rats trained under this procedure acquire training criterion
much faster than those who have been trained in the more traditional manner, they
were not as sensitive to substitution tests. Dose-response curves determined with the
"fast-trained" rats are only comparable with those of the "slow-trained" rats if the
substitution sessions were preceded with vehicle training sessions on the same day.
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Other attempts have been made to decrease the time invested in drug
discrimination studies via the development of cumulative dosing procedures. In this
procedure, an experimenter would administer a relatively low dose of the test drug,
test for substitution, then administer another dose within a relatively short period of
time (e.g., 5 min) to increase the dose currently "in the subject" before testing again.
This process is repeated until the cumulative dose administered is presumed to be
equivalent to the maximum dose to be tested for substitution in the subject. This
procedure allows for the determination of a dose-response curve within a single day,
drastically decreasing the time necessary to collect meaningful data. However, this
procedure has not yet been fully accepted, as it has at least three inherent problems
(Oveton, 1988). One main disadvantage to the cumulative dosing procedure is that the
drug-blood level of a drug in a particular organism is not always predictable after a
series of injections. Second, the results obtained from a given test trial within a
session may or may not be independent of the results obtained during the previous test
trial. Finally, a series of tests in this manner may disrupt the degree of stimulus control
established under training drug conditions (Overton, 1988). However, a researcher
can attempt to control for this effect by periodically administering a series of training
sessions in a manner consistent with the testing regimen (e.g., W D ).
Doses must be chosen very carefully when using the drug discrimination
procedure. The extent to which a given compound mimics a training drug is
dependent not only on the dose of the test drug, but the dose of the training drug as
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well (Stolerman & DMello, 1981; White & Appel, 1982b). In order to substitute for a
training drug at a relatively high dose, a high dose of the test compound is generally
required (Overton, 1971; Stolerman & DMello, 1981).
It has been commonly understood that the drug discrimination procedure is
helpful in classifying drugs, especially those suspected of high abuse potential.
However, it is as yet unknown if the discriminative stimulus effects of an abused drug
are in any way related to the subjective effects that appear to contribute to drug abuse.
Unfortunately, little attention has been directed to the effects contributing to drug
discrimination with respect to their possible contribution to drug abuse. Although the
drug discrimination procedure has been determined to be quite helpful, it is quite
limited in this regard by its very nature in that there are no other procedures available
with which to measure its reliability and validity.
Although the drug discrimination procedure appears to have some limitations
that are difficult to overcome, it remains highly regarded as a powerful tool for the
designation of drug categories (Overton, 1984), and for the assessment of neural
mechanisms underlying the stimulus effects of various psychoactive agents (Appel &
Cunningham, 1986). Its widespread acceptance as a research tool is reflected by its
use in over 2,500 experiments published between 1951 and 1996 (Stolerman, 1998).
Through these and similar procedures, MDMA has been established as having definite
discriminative stimulus properties and has since become a subject o f study in a great
many drug discrimination investigations.
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An Overview of MDMA

A Brief History o f MDMA

Methylenedioxymethamphetamine (MDMA, Figure 1) first appeared in 1912
when it was synthesized by the Merck Pharmaceutical Company in Darmstadt,
Germany, by scientists searching for an appetite suppressant for soldiers during the
First World War (Redhead, 1993; Beck & Rosenbaum, 1994). Patented in 1914
(Henry, Jeffreys, and Darley, 1992), this drug was virtually forgotten for nearly forty
years. MDMA briefly resurfaced in 1953, when the US Army Medical Center began
experimenting with the drug's anorectic properties (Redhead, 1993), but was not used
recreationally until the late 1960's, when "it seems that almost anything was tried for
it's psychedelic effects, e.g., smoking banana peels, sniffing Italian red peppers, etc."
(Mack, 1985, p. 641). The effects of this psychedelic amphetamine was o f particular
interest to "new age seekers" who used the drug to induce feelings of human
interconnectedness and well being (McDowell & Kleber, 1994). Thus, despite its
early beginnings, MDMA has only been "on the street" for about thirty years.
When the results of the Army's experimentation were made public in the early
1970's interest in the drug began to wane but, in 1976, a small group of therapists
began prescribing MDMA as an adjunct to induce communication, acceptance, and
facilitate "self-examination" (McDowell & Kleber, 1994). However, the members of
this group were hesitant to publish any of their results in fear that public knowledge of
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the drug's use might quicken illegalization and thus prevent any future research. In
1978, however, Shulgin and Nichols published the first pharmacological account of
MDMA, in which they described the drug's ability to evoke an easily controlled "state
of consciousness" characterized by enhanced self-awareness, affect, and
communication. These effects have since been widely reported among users
(Anderson, Braun, Braun, Nichols & Shulgin, 1978; Climko, Roehrich, Sweeney, &
Al-Razi, 1987; Peroutka, Newman, & Harris, 1988). Despite this publication, the
potential therapeutic use of MDMA was largely unknown to the general public and its
use was confined to a small population of recreational users (Beck & Rosenbaum,
1994). The recreational use of MDMA, however, was to see a dramatic increase in
the next few years.

NHCH
CH
Figure 1. The Chemical Structure of MDMA.

The extra medicinal use of MDMA began to climb in the early 1980's,
probably due to the efforts of some entrepreneurs from Boston known, appropriately
enough, as the "Boston Group". Through mass-production and distribution by this
new group of businessmen, the popularity of MDMA as a recreational drug began to
rise (Beck & Rosenbaum, 1994). As the demand for the drug increased, so did the
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opportunity for profit. This opportunity was seized upon by the southwest distributor
for the Boston Group who, with financing from friends in Texas, began his own
business. By using such promotional techniques as sale at commercial stores and bars,
as well as promoting "ecstasy parties" featuring a new drug that's "fun" and "good to
dance to", the Texas Group's efforts resulted in an all-time high of MDMA use (Beck
& Rosenbaum, 1994). In 1985, an estimated 35 to 200 physicians used MDMA in
practice and non medical use reached an approximate 30,000 doses per month prior to
its illegalization (American Medical News, 1985). Since MDMA has been reported to
induce feelings of connection and a certain psychomotor agitation that could be
"pleasurably relieved" by dancing, its popularity in the dance clubs seemed natural.
The drug became the status quo at all-night dance parties called raves, which have
only recently gained popularity in the United States, but have been a favorite in
England since the early 1980's (McDowell & Kleber, 1994). The drug had, however,
been illegal in England since 1977 under the Misuse of Drugs Act of 1971 (Redhead,
1993). Unfortunately, this form of popularity would quickly take a decidedly dark
turn.
A number of MDMA-related deaths began to emerge in the raves of England,
apparently due to the conditions of the clubs themselves. It had been argued that loud
noise, elevated temperature, (Randall, 1992) and dehydration (Green, Cross, &
Goodwin, 1995) may exacerbate the toxic effects of MDMA. Thus, the most
preferred place for MDMA use was also its most dangerous. It briefly became the
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custom of some rather machiavellian club owners to turn off their water supply while
hosting the raves. In this manner, they could enjoy enhanced profits by selling bottled
water. On a particularly hot day in 1992, about 15 deaths were correlated with this
practice. The British National Poisons Unit determined that the deaths were the result
of a form of heat stroke, brought on by MDMA use under conditions of dehydration
and vigorous dancing. The English government quickly mandated a continuous supply
of water at all clubs and the number of MDMA-related deaths, coincidentally,
dramatically decreased (McDowell & Kleber, 1994).
Although the Drug Enforcement Agency (DEA) of the United States had been
aware of MDMA since the early 1970's, reports of its use had been entirely too
infrequent to warrant investigation (Beck & Rosenbaum, 1994). In 1982, a DEA
spokesperson was quoted as saying "If we can get enough evidence to be sure there's
potential for abuse, we'll ban it." (Dye, 1982, p. 8). The increased popularity brought
on by the Texas Group's efforts provided the DEA with the fuel it needed to
criminalize MDMA. Due to its frequent use, the DEA requested in July of 1984 that
MDMA be placed on Schedule I of the Controlled Substances Act (CSA), a
classification that categorizes a drug as having high abuse potential and no approved
medical use. This was soon supported by a DEA chemist's contention that MDMA
demonstrates high abuse potential due to its widespread illicit sale and use, its
clandestine manufacture, and its chemical and pharmacological similarity to
amphetamine, another—already illegal—drug of abuse (Beck & Rosenbaum, 1994).
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The Texas Group responded by attempting to squeeze every bit of profit
possible from their product while it was still legal. During this period, the production
and sale of MDMA reached its peak and in the final two months or so prior to its
illegalization, a reported amount of over two million tablets were sold. This group of
salesmen began selling their product at dramatically reduced rates, creating a sort of
"going out of business sale”. Prices were said to have reduced in some areas from $25
to $8 per tablet (Beck & Rosenbaum, 1994). Although the hearings to decide whether
to criminalize MDMA were scheduled to take place in the Fall of 1985, the rampant
sale of the drug and blatant promotion at clubs and bars (Beck & Rosenbaum, 1994)
provoked Senator Lloyd Bensten (McDowell & Kleber, 1994) to petition the DEA to
place MDMA on Schedule I on an emergency basis under the Comprehensive Crime
Control Act of 1984 (Beck & Rosenbaum, 1994). On July 1, 1985, MDMA was
temporarily placed on Schedule I of the CSA although a substantial number of people,
including therapists and the clergy, were in support of a less restrictive category (much
to the surprise of the DEA) (McDowell, & Kleber, 1994).
Of course, criminalization did not eliminate the use of MDMA. A 1987
survey of college students reported that 39% still used the drug (Peroutka, 1987). If
anything, it piqued the public’s interest. After the July 1 scheduling, an explosion of
coverage of the drug appeared in the lay press (e.g., Dowling, 1985; Gerts, 1985;
Rolbein, 1985; Toufexis, 1985) and a new drug appeared. An offshoot of the Texas
Group created an analog to MDMA 3, 4-methylenedioxymethamphetamine (MDE)
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and tried to market it under the name "Eve", although the strategy was largely
unsuccessful, it prompted congress to pass the Controlled Substances Analog Act
(CSAA) in 1986 (Beck & Rosenbaum, 1986), making the creation and sale of designer
drugs illegal.
In England, the popularity of the drug carried on. In 1991, a recent study
indicated that few inquiries had been made into the England's National Poisons
Information Service (NPIS) in London until the second half of that year. This seems
of little importance to the present issue, but when a sharp increase in inquiry frequency
was noted, it piqued the researcher's curiosity. Interestingly, an increase in lab
detection of MDMA was noted which correlated nicely with the increase in NPIS
inquiries (Henry, Jeffreys, & Dawling, 1992).
Since amphetamine, the parent drug of MDMA, was not illegal at the time of
MDMA's synthesis, it may be argued that MDMA is not a designer drug in the
strictest definition of the term. Nontheless, it is considered to be one of the most
popular and well known "members" of the designer drug class. Thus, a brief
discussion of the more salient characteristics of designer drugs is warranted.

Designer Drugs: A General Discussion

A designer drug is a slight variation of a drug that is already federally
controlled, and designed to imitate the effects of the drug from which it was derived.
Each time a new drug was discovered, law enforcement agencies were required to go
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through a variety of lengthy beaurocratic procedures to have it certified as a controlled
substance (Maisto, Galizio, & Conners, 1991). Thus, prior to the enactment of the
CSAA, drug dealers could take advantage of this lapse by rapidly creating and
distributing analogs of already illegal drugs. Since it is the parent compound that is
illegal, not the analog itself, the drug distributors could sell essentially legal drugs
(Evanko, 1991) and, with rapid rates of synthesis and large-scale distribution, turn
very impressive profits. This practice, however, had some rather serious
consequences.
Hurried mass-production and low standards of quality led the distributors to
sell drugs without controlled testing or quality control. It was often unknown what
behavioral or physiological effects a designer drug would have until it was distributed.
The risks of introducing drugs contaminated with toxins were also then dramatically
increased (Carroll, 1993). To illustrate, l-methyl-4-phenyl-l, 2, 3, 6tetrahydropyridine (MPTP) was distributed as a synthetic opiate and was found to
have caused significant damage to the substantia nigra in users, resulting in
parkinsonian-like symptoms (Langston, 1985; Ballard, Tetrud, & Langston, 1985;
Kirsch, 1986). Controlling the production of designer drugs seemed insurmountable.
By the time one drug was criminalized, another legal one had taken its place. The
CSAA, which allows for the immediate classification of a novel drug as a controlled
substance, was seen as a solution to this problem (Maisto, Galizio, & Conners, 1991).
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Unfortunately, a lapse still exists between the creation of a designer drug and
its criminalization due to the lack o f sensitive assays in the agencies' possession to
detect novel compounds (Payne, Hahn, & Pinger, 1991). This "grace period"
combined with the relative affordability and increased potency makes the continued
use of designer drugs likely (Carroll, 1993). Indeed, a designer drug can be 10 to
1,000 times more potent than its parent compound (Maisto, Galizio, & Conners,
1991). For example, alpha-methyl-fentanyl is 200 times stronger than its parent
compound, morphine (Beebe & Walley, 1991).
Synthetic opiates, arylhexylamines, and phenylethylamines are three of the
most common categories of designer drugs. An exception, it seems, is crack, a form
of cocaine. Although it does not fall into any of the three categories above and has
been illegal from the outset, it has been referred to as a designer drug due to its
popularity and availability (Beebe & Walley, 1991). This discrepancy illustrates the
relatively relaxed definition the public appears to attatch to the term "designer drug".
MDMA, a phenylethylamine, is a synthetic amphetamine derivative with both
hallucinogenic and stimulant properties (Callahan & Appel, 1988; Evans & Johanson,
1986; Schechter, 1986a).

The Subjective and Behavioral Effects of MDMA

The most salient effects of MDMA in humans are subjective in nature.
MDMA users have reported an increase in affect and self-esteem, as well as enhanced
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communication and intimacy (Greer & Strassman, 1985; Schechter, 1986; Climko,
Roehrich, Sweeney, & Al-Razi, 1987; Lamb & Griffiths, 1987; Peroutka, Newman, &
Harris, 1988). Although a heightened sense of touch and mild visual hallucinations
have been reported by MDMA users (Lamb & Griffiths, 1987), the most commonly
reported effects of MDMA seem to be without the sensory distortion or dissociation
from oneself that is commonly associated with hallucinogens (Greer & Strassman,
1985; Schechter, 1986; Climko et al., 1987; Peroutka et al., 1988). This drug was
likely used as a psychotherapeutic adjunct due to its reported ability to enhance
feelings of interconnectedness and empathy (Downing, 1986; Grinspoon & Bakalar,
1986).
The subjective effects of MDMA appear to occur in three phases in humans.
The first 30-minute interval is often referred to as "The Weird Period" (WP). The WP
is often followed by a "rush" of "tingling sensations" and finally a "high" that lasts from
3 to 5-hours (Schechter, 1987). After the 3 to 5-hour high, the effects are largely
dissipated except for a mild residual sympathomimetic stimulation that can last for
several hours (Schechter, 1987). The subjective effects of withdrawal include muscle
aches, depression, drowsiness, and a deficit of concentration (Barnes, 1988).
The study of nonhuman subjects has facilitated the controlled observation of
behaviors affected by MDMA. Fortunately for many food-reinforced studies, MDMA
seems to have little, if any, anorectic effects as would be shown by the subjects' lack of
willingness to respond for food (Boja & Schechter, 1987). The behavioral effects of
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MDMA are most commonly compared to those of amphetamine. MDMA has been
noted to be self administered by rhesus monkeys and baboons (Beardsley, Balster &
Harris 1986; Lamb & Griffiths, 1986), to increase self-stimulation of the brain
(Hubner, Bird, Rassnick, & Kometsky, 1988), and decrease prepulse inhibition in a
manner similar to such psychotomimetics as apomorphine and amphetamine
(Mansbach, BrafF, & Geyer, 1989). Like amphetamine, the drug increases startle
amplitude (Mansbach et al., 1989). MDMA seems to produce an increase in
locomotor stimulation that is similar to that seen with amphetamine (Braun, Shulgin, &
Braun, 1980; Gold & Koob, 1980), but at doses that do not induce stereotypy (Gold,
Koob, & Geyer, 1988). The MDMA-induced increase of locomotor activity seems to
have a more prolonged duration than those of amphetamine and a time course that
seems to coincide with the subjective effects reported by humans (Shulgin & Nichols,
1978; Beck & Morgan, 1986). This drug has also been shown to be effective in
producing conditioned taste aversion, but is not as potent in this capacity as
amphetamine (Lin, Atrens, Christie, Jackson, & McGregor, 1993). Similar to cocaine
and amphetamine, MDMA has been demonstrated to produce conditioned locomotor
activity accomplished by consistent pairings of drug administration and salient
environmental cues (e.g., odor) (Gold & Koob, 1989). Also similar to these classical
psychostimulants, MDMA has also been demonstrated to produce conditioned place
preference (Bilsky, Hui, Hubbel, & Reid, 1990; Schechter, 1991). Interestingly, a
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neurotoxic dose regimen (20 mg/kg, delivered s.c. twice daily for 4 days) does not
change this conditioning (Schechter, 1991).
The effects o f MDMA on schedule-controlled behavior have been explored a
little more sparsely. Acute administrations of MDMA have been shown to decrease
responses in a dose-dependent manner in: mice maintained under a FR 20 schedule of
food delivery (Glennon, Little, Rosencrans, & Yousif, 1987); pigeons under both
components of a multiple FR 30 FT 3-min schedule of food delivery (Nader, Hoffman,
& Barrett, 1989); and monkeys under a repeated acquisition procedure (Thompson,
Winsauer & Mastropaolo, 1987). Frederick, Gillam, Allen and Paule (1995)
demonstrated that acute MDMA administration reduced performance accuracy in
monkeys under temporal response differentiation (TRD) and incremental repeated
acquisition (IRA) conditions. Drug administration also lowered the break point under
a progressive ratio (PR) schedule of food delivery. In each of these conditions,
response rate was not affected and no effect was found on performance under delayedmatching-to-sample (DMTS) or conditioned position responding (CPR) procedures
(Fredrick, Gillam, Allen & Paule, 1995). However, in a different study, acute
administration of MDMA induced lower performance accuracy in monkeys under a
CPR schedule (Frederick, Ali, Slikker, Gillam, Allen, & Paule, 1995).
Relatively few studies have examined the chronic effects of MDMA
administration on behavior. Zancy, Virus, and Woolverton (1989) demonstrated that
when MDMA was administered chronically to mice, milk drinking initially decreased,
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but behavioral tolerance eventually developed. In rats under an interresponse-timegreater-than-72-s (IRT > 72-s) schedule, MDMA initially decreased response rates
and reduced reinforcement rates. After chronic administration, sensitization occurred
and the effects of MDMA were more pronounced (Li, Marek, Vosmer, & Seiden,
1989). In monkeys, chronic drug administration produced tolerance to the MDMAinduced disruption of accuracy under TRD, CPR, and IRA schedules (Frederick, Ali,
Slikker, Gillam, Allen, & Paule). Finally, MDMA administration decreased the overall
response rate and accuracy of pigeons under a DMTS schedule (LeSage, Clark, &
Poling, 1993). Similar to Frederick et al. (1995), although no deterioration of
performance was noted, tolerance to the acute effects of MDMA developed after
chronic administration (LeSage, Clark, & Poling, 1993).
Although it has been repeatedly stated that the behavioral effects of MDMA
under a variety of conditions have been studied with inadequate detail, the ability of
MDMA to serve as a discriminative stimulus appears to be an exception to this
contention. Since MDMA has distinct subjective, physiological, and behavioral effects
that have been demonstrated to be similar to psychostimulant and hallucinogenic
drugs, it seems intuitive that MDMA should be able to serve as a discriminative
stimulus or substitute for other drugs that have previously been established as
discriminative stimuli. Callahan & Appel (1987) reported that although LSD and
mescaline are both hallucinogens, the discriminative stimulus effects of MDMA are
more similar to mescaline than LSD. At certain doses, MDMA has been shown to
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produce discriminative stimulus effects similar to amphetamine in pigeons (Evans &
Johnson, 1986), rats (Glennon and Young 1984), and monkeys trained to discriminate
amphetamine from saline (Kamien, Johanson, Schuster, & Woolverton, 1986).
However, amphetamine seems to have rather inconsistent effects in rats. Oberlender
and Nichols (1988) demonstrated that amphetamine substitued for MDMA in rats, but
Schechter (1989) failed to replicate this finding. Thus, it appears that the discriminable
effects of MDMA are far from completely understood.

The Discriminative Effects of MDMA

The first report that MDMA possessed stimulus discriminative control
properties came via an abstract by Glennon, Titeler, Lyon, and Yousif (1986). The
first detailed description, however, was made by Schechter (1987) who trained rats to
discriminate (±)-MDMA from saline in a two-lever procedure using an FR 10 schedule
of food delivery. Schechter reported that (±)-MDMA substituted for itself in a dosedependent manner, as did its optical isomers. The R(-) enantiomer, however, was
shown to be slightly less potent than the S(+) in this regard. Although (+)-MDMA has
been reported to be more active than the racemate (Anderson, Bronson, Braun,
Nichols, & Shulgin, 1978), (±)-MDMA is a more potent substitute for itself than either
isomer (Schechter, 1987). This finding is supported by in vitro findings by Nichols,
Lloyd, Hoffman, Nichols, & Yim (1982), which demonstrated that (±)-MDMA was
more potent in promoting monoamine release than either isomer. The discriminative
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stimulus properties of MDMA seem to have a time-course o f 10 to 90 min and rats
demonstrate 100% drug-appropriate lever-pressing when tested at 20 and 60 min
following MDMA administration (Schechter, 1987). The (-) isomer of MDMA also
appears to have a longer time-course than does the (+) isomer (Baker, Virden, Miller,
& Sullivan, 1997).
The results of drug discrimination studies using (±)-MDMA as a training drug
are summarized in Table 1. These findings appear to correlate well with some
subjective reports in humans. For example, the subjective effects of 3, 4methylenedioxyamphetamine (MDA), a major metabolite of MDMA (Fitzgerald,
Blanke, Narisamhachari, Glennon, & Rosencrans, 1987) and a recreational drug of
lesser popularity (Cho, Hiramatsu, Distefano, Chang, & Jenden, 1990; Yousif,
Fitzgerald, Narasimhachari, Rosencrans, Blanke, & Glennon, 1990), seem to resemble
the subjective effects of MDMA in humans (Shulgin & Nichols, 1978). Likewise,
MDMA has been shown to substitute in nonhuman subjects trained to discriminate
MDA (Glennon & Young, 1984) or its isomers (Broadbent, Appel, Michael, & Ricker,
1992) from vehicle. Racemic MDMA also substitutes for its N-ethyl derivative Nethyl-3, 4-methylenedioxyamphetamine (MDE; Eve) (Boja & Schechter, 1987) and
produces stimulus generalization to N-methyl-l-(l, 3-bensoioxyl-5-yl)-2butanamine(MBDB), the alpha-ethyl homologue of MDMA (Oberlender & Nichols,
1988). MDE also substitutes for (±)-MDMA as does N-hydroxy MDA (N-OH-
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Table 1

Results of Substitution Tests in Drug Discrimination Procedures
Using (±)-MDMA as a Training Drug

Drug

Substitution? (Y/N/??)

MDE

Y

N-OH-MDA

Y

3-OH-PMMA
3, 4-DMA
N-Me-3, 4-DMA
PMA
PMMA
LSD

N
N
N
N
Y
Y

DOM

N

ibogaine

N

amphetamine
??
fenfluramine

Y

norfenfluramine
TFMPP
PCA
THBC
MMAI

Y
Y
Y
Y
Y

8-OH-DPAT
DOI
PIA
5-iodo-2-aminodan
MTA
apomorphine
I-cathinone

N
N
Y
Y
Y
N
N

Source
Glennon & Meisenheimer
(1989)
Glennon & Meisenheimer
(1989)
Glennon & Higgs (1992)
Glennon & Higgs (1992)
Glennon & Higgs (1992)
Glennon & Higgs (1992)
Glennon & Higgs (1992)
Oberlender & Nichols
(1988)
Oberlender & Nichols
(1988)
Schechter & Gordon
(1993)
Y Oberlender & Nichols
(1988)
N Schechter (1989)
Baker et al. (1995);
Schechter (1986a, 1989)
Schechter (1989)
Schechter (1989)
Schechter (1986a)
Schechter (1986b)
Marona-Lewicka &
Nichols (1994); Huang et
al. (1992)
Glennon (1987a)
Glennon (1987a)
Fuller et al. (1980)
Nichols et al. (1991)
Johanson et al. (1991)
Young & Glennon (1986)
Young & Glennon (1986)
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MDA), another structural analogue of MDMA (Glennon & Meisenheimer, 1989).
Although MDMA, MDE, and N-OH MDA have similar subjective effects, N-OH
MDA appears to be slightly more potent than MDMA, and MDE is slightly less potent
(Braun, Shulgin, & Braun, 1980). These findings illustrate the similarities betwen the
results indicated from drug discrimination studies and human reports of MDMA's
subjective effects.
In an attempt to determine whether metabolite-related analogues of MDMA
produce stimulus effects similar to those of their parent compound, Glennon and Higgs
(1992) performed substitution tests with several MDMA analogues in rats trained to
discriminate (±)-MDMA from saline. The five analogues tested were: N-monomethyll-(3-hydroxy-4-methoxyphenyI)-2-aminopropane (3-OH-PMMA); l-(3, 4dimethoxyphenyl)-2-aminopropane (3, 4-DMA); N-Me 3, 4-DMA; PMA; and Nmethyl-l-(4-methoxyphenyl)-2-aminopropane (PMMA). Only PMMA produced (±)MDMA-like responding.
Attempts to classify the discriminative stimulus effects of MDMA, however,
have yielded mixed results. Table 2 summarizes the results of experiments attempting
to delineate the discriminative effects of the optical isomers of MDMA. Although
MDMA has been reported to have hallucinogenic effects and affect the serotonin (5HT) neuronal systems, neither isomer of MDMA has been shown to substitute for the
hallucinogens 2, 3-dimethoxy-4-methylisopropylamine (DOM) (Glennon, Young,
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Table 2
Results of Substitution Tests in Drug Discrimination Procedures Using
(+)-MDMA or (-)-MDMA as a Substitution or Training Drug

Procedure

Drug

Substitution?

(+)-MDMA as
training drug

mescaline
LSD
cocaine
amphetamine

N
N
N
N

Baker et al. (1995)
Baker et al. (1995)
Baker et al. (1995)
Baker et al. (1995)

(-)-MDMA as
training drug

mescaline
LSD
cocaine
amphetamine

N
Y
N
N

Baker et al.
Baker et al.
Baker et al.
Baker et al.

(+)-MDMA as
substitution drug

DOM

N

a-MeT
LSD

N
N

mescaline

Y

amphetamine
??

(-)-MDMA as
substitution drug

DOM

N

a-MeT
LSD

N
N

mescaline

Y

amphetamine

N

Source

(1995)
(1995)
(1995)
(1995)

Glennon et
al.(1982)
Glennon (1993)
Callahan & Appel
(1988)
Callahan & Appel
(1988)
Y Glennon et al.
(1988)
N Oberlender &
Nichols (1988)
Glennon et al.
(1982)
Glennon (1993)
Callahan & Appel
(1988)
Callahan & Appel
(1988)
Oberlender &
Nichols (1988)
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Rosencrans, & Anderson, 1982), a-methyltryptamine (a-MeT) (Glennon, 1993) or
LSD (Callahan & Appel, 1988). However, both isomers were found to substitute for
the hallucinogen mescaline (Callahan & Appel, 1988) and the racemate generalized to
the a-ethyl homologues of both DOM and a-MeT (Glennon, 1993). Additionally,
LSD was found to substitute for (±)-MDMA, but DOM did not (Oberlender &
Nichols, 1988). Yet, another study indicated that mescaline did not substitute for
either isomer of MDMA, and LSD only substituted for (-)-MDMA (Baker, Broadbent,
Michael, Matthews, Metosh, Saunders, West, & Appel, 1995). Further, Schechter and
Gordon (1993) report that ibogaine, a drug that produces both stimulant (Gershon &
Lang, 1962) and hallucinogenic (Clineschmidt, Zacchel, Totaro, Pflueger, McGruffin,
& Wishoutsky, 1978) effects in humans, demonstrated no stimulus generalization to
(±)-MDMA. It is also interesting to note that, despite the similarities of discriminative
stimulus control found between (+)-MDA and cocaine (Broadbent, Michael, & Appel,
1989; Broadbent, Appel, Michael, & Ricker, 1992), this CNS stimulant was found to
substitute for neither isomer of MDMA (Baker, Broadbent, Michael, Matthews,
Metosh, Saunders, West, & Appel, 1995). It is also rather interesting to point out that
in rats trained to discriminate A^-tetrahydrocannibinol (THC), (±)-MDMA produced
no drug-appropriate responding (Barrett, Wiley, Baslter, & Martin, 1995).
Table 3 summarizes the results of investigations of the effects of (±)-MDMA
as a substitution drug in rats trained to discriminate a variety of psychoactive drugs.
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Although (+)-MDMA was reported to substitute for amphetamine in one study
(Glennon, Yousif, & Patrick, 1988) other researchers reported no substitution with
either isomer (Oberlender & Nichols, 1988) or the racemate (Oberlender & Nichols,
1988; Glennon & Meisenheimer, 1989). However, as previously stated, racemic
MDMA was found to substitute for amphetamine in studies using rats (Glennon &

Table 3
Results of Substitution Tests in Drug Discrimination Procedures
Using (±)-MDMA as a Substitution Drug

Drug

Substitution?

MDA
(+)-MDA
(-)-MDA
MDE
MBDB

Y
Y
Y
Y
Y

a-ethyl homologue of DOM
a-ethyl homologue of aMeT
amphetamine

Y
Y

??

methamphetamine
fenfluramine
lisuride
bromocriptine
TFMPP
1-cathinone
THC

N
Y
N
N
N
Y
N

Source
Glennon & Young (1984)
Broadbent et al. (1992)
Broadbent et al. (1992)
Boja & Schechter (1987)
Oberlender & Nichols
(1988)
Glennon (1993)
Glennon (1993)
Y Glennon & Young (1984);
Evans & Johanson (1986);
Kamien et al. (1986)
N Oberlender & Nichols
(1988); Glennon &
Meisenheimer (1989)
Glennon & Higgs (1992)
Schechter (1986a, 1989)
White & Appel (1982a)
Holohean et al. (1982)
Schechter (1988b)
Schechter (1986a)
Barret et al. (1995)
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Young, 1984), pigeons (Evans & Johanson, 1986), and monkeys (Kamien, Johanson,
Schuster, & Woolverton, 1986). Further, Oberlender and Nichols (1988)
demonstrated that (+)-amphetamine substitutes for (±)-MDMA . However, Schechter
(1989) failed to replicate this finding. Glennon and Higgs (1992), interestingly,
reported that MDMA did not produce stimulus generalization to methamphetamine.
When a drug is found to substitute for another compound, but is not substituted by the
compound when the initial test drug is used as a training drug, the substitution is
referred to as asymmetrical. Although amphetamine and (±)-MDMA yield
contradictory results, findings have been more consistent regarding the 5-HT releasers
such as the amphetamine derivative fenfluramine, and its major metabolite
norfenfluramine (Schechter 1986a, 1989).
Although fenfluramine is structurally similar to amphetamine and both have
been used therapeutically as anorectics (Evans, Zancy, & Johanson, 1990), some
significant differences may account for this apparent lack of discriminative similarity
with regards to MDMA substitution: Amphetamine facilitates the release of the
catecholamines, particularly dopamine (DA). (Glowinski, 1970; Leibowitz, 1978). In
contrast, fenfluramine facilitates 5-HT release (Garattini, Barroni, Mennini, &
Samanin, 1981; Jespersen & Scheel-Kruger, 1973). Interestingly, amphetamine has
been found to be freely self-administered in monkeys (Balster & Schuster, 1973) and
in humans (Johanson & Uhlenhuth, 1982), but this has not been demonstrated with
fenfluramine (Johanson & Uhlenhuth, 1982; Woods & Tessel, 1974). Further, where
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fenfluramine is found to produce non-stimulant-like subjective effects in humans
(Chait, Uhlenhuth, & Johanson, 1986; Gotesdam & Gunner, 1972; Griffith, Nutt, &
Jasinski, 1975) and sedative effects in rats (Ziance, Sipes, Kinnard, & Buckley, 1972),
amphetamine increases rodent locomotor activity (Cox & Maickel, 1972) and
produces stimulant-like subjective effects in humans (Chait, Uhlenhuth, & Johanson,
1986).
Inconsistencies such as the asymmetrical cross-substitution of MDMA and
amphetamine also appear to indicate that the extent to which the discriminative
stimulus effects of MDMA are amphetamine- or hallucinogen-like may depend on the
training drug and the procedures used. Schechter (1989), for example, utilized an FR
10 food-reinforced schedule while Oberlender and Nichols (1988) used an FR 50
schedule and the dose at which amphetamine substituted for (±)-MDMA disrupted
responding in nearly half of the subjects. Glennon and Meisenheimer (1989), on the
other hand, utilized a VI 15 schedule of sweetened powdered milk delivery during 15
min sessions held 15 min after injection. In the study by Evans & Johanson (1986),
pigeons were trained on a 3-key FR 30 food delivery schedule to discriminate
fenfluramine, amphetamine, and saline vehicle from one another. When administered
(±)-MDMA, two of the three pigeons responded on the amphetamine-appropriate key,
and the other responded on the key previously active after fenfluramine administration.
Further, Stolerman and DMello (1981) suggest that drug-produced stimulus control in
general may be mediated by multiple drug effects. Compounds without partially
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overlapping profiles of action may have to be administered in relatively larger doses to
provide shared effects with an intensity adequate for stimulus generalization. Perhaps
it is the case that MDMA and amphetamine have profiles of action which overlap to
the extent that some generalization may occur, but differ significantly with respect to
their primary pharmacological activities (Oberlender & Nichols, 1988). The degree to
which these factors may influence the discriminative stimulus effects of a given drug
has not heretofore been determined.
Several attempts have been made to assess the neural mechanisms of the
discriminable effects of MDMA via the drug discrimination procedure. The indirect 5HT releaser, norfenfluramine, the 5-HT releaser and putatively specific 5-HTjg
agonist, N-3-triflouromethylphenylpiperazine (TFMPP) (Schechter, 1989), and the 5HT releasers p-chloramphetamine (PCA) and fenfluramine have been shown to
substitute for (±)-MDMA (Schechter, 1986a) or its isomers (Baker et al., 1995).
Tetra-hydro-b-carboline (THBC), which has been shown to be active in 5-HT systems,
has also been shown to substitute for MDMA (Schechter, 1986b), as did the selective
5-HT releasing agent 5-methoxy-6-methyl-2-aminodan (MMAI) (Marona-Lewicka &
Nichols, 1994). However, the 5-HT j ^

agonist 8-OH DP AT and the 5-HT2 agonist

DOI have been shown to not substitute for (±)-MDMA (Glennon, 1987a), nor does
(±)-MDMA substitute for lisuride (White & Appel, 1982a) or bromocriptine
(Holohean, White, & Appel, 1982). Although TFMPP substitutes for (±)-MDMA,
this relationship appears asymmetrical in that TFMPP yielded no stimulus
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generalization to (±)-MDMA (Schechter, 1988b). However, the discriminative
stimulus effects o f MDMA and each isomer have also been shown to be attenuated by
the 5-HT2 receptor antagonist pirenpirone (Schechter, 1989; Baker, et al., 1997).
Further, p-idoamphetamine (PIA), a 5-HT neurotoxic halogenated amphetamine which
inhibits [^C]-5-H T uptake and blocks the degeneration of 5-HT by mitochondial
monoamine oxidase (Fuller, Snoody, Snoody, Hemrick, Wong, & Malloy, 1980), and
its non neurotoxic analogue, 5-iodo-2-aminodan, have both been demonstrated to
substitute for (+)-MDMA (Nichols, Johanson & Oberlender, 1991), as has 5methoxy-6-methyl-2-aminoindan (MMAI), which possesses a high level of 5-HT
activity and virtually no DA activity (Huang, Marona-Lewicka, & Nichols, 1992). pMethylthioamphetamine (MTA), a potent 5-HT releaser has also been demonstrated to
substitute for (±)-MDMA (Johanson, Frescas, Oberlender, & Nichols, 1991). These
findings suggest a serotonergic involvement in the discriminative stimulus effects of
MDMA. In another study, however, pirenperone has been shown not to block the
discriminative stimulus effects of (±)-MDMA in mice (Rosencrans & Glennon, 1987).
Table 4 provides a synopsis of similar research that explored the ability of a
variety of compounds to attenuate drug appropriate responding during training-dose
substitution tests in subjects trained to discriminate (±)-MDMA from saline. The less
selective 5-HT antagonist metergoline was also found to have no effect on the
discriminative stimulus properties of either isomer of MDMA (Baker et al., 1995).
However, the 5-HT3 antagonists LY27854 and zacopride have been shown to block
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(±)-MDMA discrimination (Glennon, Higgs, Young, Issa, 1992). Although (+)MDMA has been shown to have some dopaminergic properties, the DA antagonists
haloperidol (Young & Glennon, 1986) and CGS10746B (Altar, Wesley, Liebman,
Gerhard, Kim, Welsh, & Wood, 1987) were shown not to block (±)-MDMA
discrimination. Similar to some of the results found with amphetamine, the direct DA
agonist, apomorphine, and the indirect DA agonist, 1-cathinone, were shown not to
substitute for (±)-MDMA, (Young & Glennon, 1986), but (±)-MDMA substituted for
1-cathinone (Schechter, 1986a).

Table 4
Results of Antagonism Tests in Drug Discrimination Proceduress
Using (±)-MDMA as a Training Drug

Drug

Substitution?

Source
Y Schechter (1989)

pirenperone
99

metergoline
LY27854
zacopride
haloperidol
CGS10746B

N
Y
Y
N
N

N Rosencrans & Glennon
(1987)
Baker et al. (1995)
Glennon et al. (1992)
Glennon et al. (1992)
Young & Glennon (1986)
Altar et al. (1987)

This seemingly exhaustive inventory of findings underscores the difficulty in
establishing conclusions in reference to the neural mechanisms mediating the
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discriminative stimulus effects of MDMA. It is likely to be the case that, although (-)MDMA appears to be more serotonergic than (+)-MDMA, the discriminative stimulus
effects of (±)-MDMA comprise a complex cue involving both dopaminergic and
serotonergic mechanisms, thereby resulting in asymmetrical substitution and partial
antagonism at best from the more selective dopaminergic or serotonergic compounds.
MDMA, therefore, produces a stimulus effect that is similar to, but more complex than
either hallucinogens or stimulants (Evans, Zancy, & Johanson, 1990). Wood, Lai,
Yaden, and Emmett-Oglesby (1985) suggest that the subjects discriminate drug effects
based on the most salient component of the training discriminative stimulus. Subjects
trained to discriminate a more selective component of this complex cue may generalize
partially to a minor component of a compound discriminative stimulus. This is
supported by the finding that the maximum 5-HT release occurs at 30 min and
maximum DA release occurs at about 90 min (Yamamoto & Spanos, 1988).
Interestingly, this change in peak neurotransmitter release corresponds to the WP
reported in human subjects.
As the reader has surely noted by now, much of the drug discrimination
research involving MDMA has conspicuously physiological overtones. Thus, a brief
treatment touching on these effects should provide the reader with a great deal of
helpful background that may be of considerable interest to the present study.
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The Physiological and Neurochemical Effects of MDMA

MDMA has been shown to facilitate the presynaptic release of 5-HT
(Johnson, Hoffman, & Nichols, 1986; Schmidt, Levin & Lovenberg, 1987; McKenna,
Guan, & Shulgin, 1991) in rat brain synaptosomes (Nichols, Lloyd, Hoffman, Nichols,
& Yim, 1982), caudate slices (Schmidt, Levin, & Lovenberg, 1987) and hippocampal
slices (Johnson, Hoffman, & Nichols, 1986). DA release is also noted in the rat
caudate nucleus (Johnson, Hoffman, and Nichols, 1986; Yamamoto & Spanos, 1988).
Interestingly, MDMA has also been shown to inhibit the reuptake of 5-HT (Gold &
Koob, 1989) and, to a lesser extent DA (Steele, Nichols, & Yim, 1987) into
hippocampal synaptosomes.
High doses of MDMA have also been shown to decrease the firing rates o f a
subpopulation of 5-HT neurons in the dorsal and median raphe, leaving DA neurons
unaffected. This implies that the effects of MDMA are mediated via a subpopulation
of 5-HT neurons (Piercy, Lum, & Palmer, 1990). Interestingly, MDMA appears to
facilitate DA release by way of 5-HT2 receptor activity (Schmidt, Fayadel, Sullivan &
Taylor, 1992).
The optical isomers of MDMA appear to have differential neurochemical
effects. As mentioned earlier, the positive enantiomer of MDMA appears to be a more
potent DA releaser than (-)-MDMA (Hiramatsu & Cho, 1990; McKenna et al., 1991;
Johnson, Frescas, Oberlender, & Nichols, 1991) and (-)-MDMA binds to 5-HT
receptors with higher affinity than (+)-MDMA (Lyon, Glennon, & Titeler, 1986).
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Further, (+)-MDMA is not only more active than (-)-MDMA, but it is more active
than the racemate as well (Anderson, Bronson, Braun, Nichols, & Shulgin, 1978).
Interestingly, in a case study by Moore, Mozayani, Fierro, and Poklis (1996) helped
determine that (+)-MDMA may metabolize more quickly than the negative isomer.
When a 20 year old victim of fatal MDMA toxicity was subjected to autopsy, much
more (-)-MDMA was found in the subject's system than was the positive enantiomer,
indicating that~by the time of the victim's death-most of the (+)-MDMA had already
been metabolized.
Mild MDMA toxicity seems to be characterized by agitation, tachycardia,
hypertension, dilated pupils and sweating. Severe toxicity is often indicated by
disseminated intravascular coagulation (DIC), hyperthermia, and acute renal failure
(Henry Jeffreys, & Dawling, 1992). MDMA-related deaths are likely to be due to
heat stroke, in which hyperthermia is accompanied by DIC (Henry, Jeffreys, &
Dawling, 1992). Demirkiran, Jankovic, and Dean (1996) provided a summary of 16
MDMA-related case studies that indicates that MDMA toxicity occurs with a rather
rapid onset (15 min to 6 h). More interestingly, their synopsis implied that toxicity, for
some mysterious reason, does not seem to be well correlated with dose. One subject
suffered severe toxicity within 15 min and died after taking a single tablet, where other
subjects had managed to swallow some 47 pills (with an MDMA plasma level of 7.72
mg/1) with only hypertension and tachycardia as symptoms of toxicity. Still other
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subjects have achieved a plasma level of 4.05 mg/1 (18 tablets) with no complaints
whatsoever, yet others have died with levels as low as 0.05-1.26 mg/1.

The Physiological Effects of MDMA Neurotoxicity

MDMA has also been demonstrated to have potentially neurotoxic effects
(Stone, Johnson, Hanson, & Gibb, 1988) and the induction of this neurotoxicity may
be accomplished by a plethora of administration methods. Short- and long-term
decreases in 5-HT and its major metabolite, 5-hydroxyindoIeacetic acid (5-HIAA)
concentrations, tryptophan hydroxylase (TPH, a rate-limiting step in 5-HT synthesis)
activity, and degeneration of fine serotonergic axon terminals have been demonstrated
in lab animals after subcutaneous (s.c.) (Commins, Vosmer, Virus, Woolverton,
Schuster, & Seiden, 1987; Battaglia, Yeh, & DeSouza, 1988; Ricaurte, Fomo,
Wilson, DeLanney, Irwin, Molliver, & Langston, 1988) or oral (Ali, Newport, Bailey
& Slikker, 1990; Ali, Newport, Scallet, Binienda, Ferguson, Bailey, Paule, & Slikker,
1993; Ali, Scallet, Newport, Lipe, Holson, & Slikker, 1989; Finnegan, Ricaurte,
Ritchie, Irwin, Peroutka, & Langston, 1988; Ricaurte, DeLanney, Irwin, & Langston,
1988; Slikker, Ali, Scallet, Frith, Newport, & Bailey, 1988; Slikker, Holson, Ali,
Kolta, Paule, Scallet, McMillan, Bailey, Hong, & Scalzo, 1989) administration of (±)MDMA at relatively high doses (10-40 mg/kg for rats, 5-10 mg/kg for monkeys) for a
few consecutive days (generally four). Ten to 20 mg/kg s.c. injections of (±)MDMA elicits whole brain decreases of 5-HT, [-^Hj-5-HT uptake and TPH within 3
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hours in rats—a decrement in 5-HT activity which is known to last for weeks even after
a single dose (Schmidt, 1987, Schmidt & Kehne, 1990). Depletions of 5-HT (55%)
and 5-HIAA (40%) in the frontal cortex, as well as in the whole brain (70%) of the rat
are common findings in MDMA neurotoxicity studies (e.g., Slikker, Ali, Scallet, Frith,
Newport, & Bailey, 1988). Robinson, Castaneda, and Whishaw (1993) noted a 72%
decrease in whole-brain 5-HT levels (32.3% in the caudate nucleus) with no effect on
dopamine (DA) levels in rats that were given i.p. injections of (±)-MDMA (10
mg/kg) every 12 hours for eight injections. Though this depletion was noted 35 to 40
days after the injection regimen completed, such long-term depletion by high, repeated
doses of (±)-MDMA are not uncommon. Ricaurte and colleagues (e.g., Ricaurte,
DeLanney, Irwin, & Langston, 1988; Ricaurte, Martello, Katz, & Martello, 1992)
noted such effects up to 18 months after injection.
Apparently, multiple injections enhance this neurotoxic effect. Indeed, it has
been noted that a multiple injection regimen results in the loss of immunohistologically
labeled 5-HT terminals (but not cell bodies). The terminal loss achieved by this and
many other neurotoxic regimens seems specific to the fine axons radiating from the
dorsal raphe, sparing the beaded axons (Battaglia, Yeh, & DeSouza, 1988; Wilson,
Ricaurte, & Molliver, 1989). Although systemic injection seems to be the most
popular method of inducing neurotoxicity, other avenues have been explored. Oral
MDMA (5-10 mg/kg, bid x 4 days) administration has been shown to decrease 5-HT
and 5-HIAA levels in the hippocampus, hypothalamus, thalamus, and frontal cortex in
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squirrel monkeys (Ricaurte, DeLanney, Irwin & Langston, 1988; Insel, Battaglia,
Johanssen, Massa, & DeSouza, 1989). Ricaurte, DeLanney, Irwin, and Langston
(1988) noted a decrease in 5-HT in the thalamus and hypothalamus two weeks after a
single oral dose o f 5 mg/kg MDMA. Similar findings have been noted in the
hippocampus in rhesus monkeys after an oral dose of 2.5 mg/kg (Ali, Newport,
Scallet, Binienda, Ferguson, Bailey, Paule, & Slikker, 1993). These doses appear to
be remarkably low as compared to those previously discussed. Indeed, oral
administration appears to be about half as effective in inducing neurotoxicity as s.c.
administration in squirrel monkeys (Ricaurte, et al., 1988). However, nonhuman
primates are known to be more sensitive to MDMA neurotoxicity than laboratory
rodents (Steele, McCann, & Ricaurte, 1992; Ricaurte & McCann, 1992). Another
note of interest is that the offspring of pregnant rats that were gavaged up to 10 mg/kg
MDMA every other day from gestational days 6 to 18 did not demonstrate any
neurotoxic effects (St. Omer, Ali, Holson, Durhart, Scalzo, & Slikker, 1991).
Any changes found after such administrations are often reported as evidence of
neurotoxicity (Frederick, Ali, Slikker, Gillam, Allen & Paule, 1995). McKenna and
Peroutka (1990) differentiated between what they called "long term" and "short term"
neurotoxicity. Short term neurotoxicity occurs in less than 24 hours and is
characterized by rapid decreases in 5-HT and its major metabolite 5-HIAA, as well as
a corresponding decrease in TPH. Within two to four hours, however, 5-HIAA levels
begin to return to normal. Long-term neurotoxicity, according to McKenna and
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Peroutka, takes longer than 36 hours to take hold and is also characterized by a
decrease in 5-HT, 5-HIAA, and TPH—only considerably slower. In this case, there is
no recovery from long-term neurotoxicity as yet noted, and the aforementioned
degeneration in 5-HT terminals is additionally noted. As noted earlier, this loss in 5HT terminals is pretty well restricted to those on axons from cells originating in the
dorsal raphe nucleus (OHeam, Battaglia, & DeSouza, 1988; Wilson, Ricaurte, &
Molliver, 1989).
Interestingly, the effects of MDMA on DA levels are variable and believed to
depend, indirectly, on serotonin release (Schmidt, Wu, & Lovenberg, 1986; Stone,
Stahl, Hanson, & Gibb, 1986; Commins, Vosmer, & Virus, 1987; Yamamoto &
Spanos, 1989; Gazzara, Takeda, Cho, & Howard, 1989), although DA seems to play a
major role in this neurotoxicity (Glennon, Young, Rosencrans, Anderson, 1982).
Increased levels of DA due to chronic administration of MDMA to monkeys have
been found in the caudate nucleus, and a trend toward the increase of DA has been
found in the frontal cortex and hippocampus of the monkey (Frederick, et al., 1995).
Frederick et al. have also noted increased levels of 5-HT in the hippocampus, though
5-HT turnover was significantly decreased. This may be due to a decrease in
hippocampal 5-HT receptor uptake sites or the lack of metabolism of 5-HT by
monoamine oxidase (MAO) as compared to control monkeys. A decrease of 5-HT
concentration was found, but turnover rate was unaffected in the frontal cortex of the
subjects. Neither the frontal cortex, the caudate nucleus, nor the hippocampus showed
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a decrease o f 5-HT uptake sites as compared to those regions in control monkeys
(Frederick et al., 1995). Also, MDMA neurotoxicity in squirrel monkeys has been
noted to leave the major metabolite of DA, homovanillic acid (HVA), and 3methoxy-4-hydroxyphenethylgIycol (MHPG), a major norepinephrine (NE) metabolite
relatively unaltered (Ricaurte, DeLanney, Irwin & Langston, 1988; Insel, Battaglia,
Johanssen, Massa, & DeSouza, 1989). Research with nonhuman primates, however,
must be interpreted with a certain degree of care because, as noted earlier, they are
more permanently and severely affected by MDMA neurotoxicity than rats and mice
(Steele, McCann, & Ricaurte, 1992; Ricaurte & McCann, 1992).
Regardless of the species, however, it appears that MDMA neurotoxicity
involves the 5-HT terminal regions of the hippocampus, neostriatum, and cerebral
cortex in rodents as well as nonhuman primates (Ricaurte, Fomo, Wilson, DeLanney,
Irwin, Molliver, & Langston, 1988; Stone, Stahl, Hanson, & Gibb, 1987; Battaglia,
Yeh, & DeSouza, 1988) with one interesting exception. A subtle inconsistency is
noted between certain species when administered a neurotoxic MDMA regimen.
Where a decrease in 5-HT and 5-HT terminal cell loss is evident in the rat while the
DA system is somewhat unharmed, this is not the case with the mouse. In the latter
organism, it is the DA system that is damaged, leaving the 5-HT system relatively
intact (Stone, Hanson, & Gibb, 1987; Logan, Laverty, Sanderson, & Yee, 1988;
O'Callaghan & Miller, 1994).
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The Potential Causes o f MDMA Neurotoxicity

The midbrain raphe nuclei provide the 5-HT innervation for the entire
forebrain and have rather high concentrations of 5-HT receptor sites (Hrdina, Foy,
Hepner, & Summers, 1990). Direct application of MDMA to this area in vitro
increases 5-HT release (Sprouse, Bradberry, Roth, & Aghajanian, 1989) which
eventually results in a decrease in cellular activity. Paris and Cunningham (1991)
astutely noted that this may indicate that the dorsal raphe may be a target for MDMA
neurotoxicity. However, intracerebroventicular (i.c.v.), injections of MDMA into the
dorsal or median raphe did not yield any indications of neurotoxicity (Schmidt &
Taylor, 1988; Paris & Cunningham, 1991).
In the light of such findings, it has been suggested that a metabolite of MDMA
may be the prime mover in the brain to bring about neurotoxicity. However, its major
metabolite, MDA, demonstrated as little neurotoxicity as MDMA when intracranially
injected (Schmidt & Taylor, 1988). However, 2, 4-bis-(glutathion-s-yl)-amethyldopamine, a putative metabolite of MDA—thus an indirect metabolite of
MDMA—results in a neurotoxic syndrome when injected i.c.v. that is very similar to
that seen with systemic MDMA administration (Miller, Lau, & Monks, 1997).
As mentioned previously it is likely that MDMA neurotoxicity may be partially
due to DA action modulated by 5-HT activity. This contention is supported by the
finding that although the 5-HT 2 agonist, l-(2, 5-dimethoxy-5-iodophenyl)-2aminopropane (DOI) increased sensitivity to neurotoxic MDMA dosing (Gudelsky,
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Yamamoto, & Nash, 1994) while 5-HT depletion by p-chloramphetamine (PCA) did
not protect against 5-HT axon terminal damage (Brodkin, Malyala, & Nash, 1993).
However, DA depletion by a-methyl-p-tyrosine (AMPT) and lesions produced in the
substantia nigra by 6-OHDA attenuate the long-term depletion of 5-HT in the brain
(Brodkin, Malyala & Nash, 1993; Schmidt, Black, & Taylor, 1990; Stone, Johnson,
Hanson, & Gibb, 1988). Thus, it is tempting to conclude that the neurotoxicity may
be due to an excessive and prolonged exposure to DA elicited by the 5-HT release
brought about by MDMA (Stone, et al., 1988; Nash, 1990). However, the search for
the cause of MDMA neurotoxicity does not neatly end with such a convenient
conclusion.
Hiramatsu, Kumagi, Unger, and Cho (1990) suggested that neurotoxicity
might involve the production of oxygen-based free radicals during the breakdown of
MDMA. During such a process, both O2 and H2 O are produced (Graham, Tiffany,
Bell, & Gutnecht, 1978; Cohen & Heikkila, 1974), which may produce an
overabundance of oxidative stress that can contribute to the destruction of the 5-HT
terminals. Of course, this may also occur during the breakdown of the excessive DA
released by MDMA (Cadet, Landheim, Hirata, Rothman, Ali, Carlson, Epstein, &
Moran, 1995).
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MDMA Neurotoxicity In Humans

It is important to note at this point that physiologically functional impairments
associated with MDMA neurotoxicity, it seems, are few and far between. Poland
(1990) noted that adrenocorticotropin hormone release is decreased and prolactin is
increased in rats after a neurotoxic treatment regimen of MDMA. Also, after
neurotoxic dosing, rats appear to have an increased metabolic rate, evaporative water
loss, and heightened colonic temperature (Gordon, Watkinson, O'Callaghan, & Miller,
1991). Such indications of MDMA-induced dehydration seems consistent with the
toxicity found in humans at generally lower doses. Further, Gordon et al.'s (1991)
observation that most of the rats (66%) died after a single dose of 20 mg/kg when
their environmental temperatures were elevated (25-30°C) seem to mimic the
unfortunate demise of the few human users in 1992 who have died in similarly warm
environments (e.g., rave parties).
It is important to note, however, that it is presently uncertain as to whether
MDMA is neurotoxic to humans. The reported serotonergic depletion induced by
MDMA in primates and rodents is generally due to doses of the drug that are greater
than those used by humans (Greer & Strassman, 1985). However, since the
nonhuman primate is considerably more "at risk" for neurotoxicity than the laboratory
rodent, and the dose for nonhuman primate neurotoxicity is only roughly double to the
doses generally self-administered by humans (1.7 to 2.7 mg/kg in humans), some alarm
has been raised as to the possibility of MDMA neurotoxicity in humans (Ricaurte,
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DeLanney, Wiener, Irwin, & Langston, 1988). Indeed, there has been a considerable
recent increase in reported psychiatric complaints by MDMA users such as anxiety,
paranoid psychosis, and depression (Series, Boeles, Dorkins, & Peveler, 1994;
McGuire & Fahy, 1991; McCann & Ricaurte, 1991).
However, determining whether or not a human has actually been exposed to a
neurotoxic dose is difficult at best without performing postmortem examinations of the
subject's brain tissue. Rather than passively waiting around for a given MDMA user
to expire, a few researchers have attempted to verify MDMA neurotoxicity via CSF
samples obtained by way of lumbar punctures in carefully screened MDMA users who
have not taken the drug for an extended period of time (generally about two to six
weeks). In this way, 5-HIAA or HVA levels may be measured, and neurotoxicity is
assumed if long-term levels of these metabolites are observed. For example, Ricaurte,
Finnegan, Irwin, and Langston (1990) found a decrease in 5-HIAA levels among
MDMA users, but Peroutka, Pascoe, and Faull (1987) did not. McCannn, Ridenour,
Shaham, and Ricaurte (1994), however, detected potentially neurotoxic effects and
some rather interesting gender effects as well. While all of the subjects had decreased
levels of HVA and 5-HIAA relative to controls, female MDMA users had significantly
lower levels of both metabolites than did their male counterparts.
Other studies have attempted to determine neurotoxicity in humans by way of
the symptoms presumed to be manifested by a deficiency of 5-HT. One study (Allen,
McCann, & Ricaurte, 1993) determined that there were significant differences in the
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quality of sleep obtained by MDMA users after two weeks o f abstinence than by non
users. MDMA users acquired 19 min less total sleep than did non-using control
subjects. Users also spent 23.2 min less time in non-REM sleep and 37 min less in
stage two sleep. However, it is important to interpret these findings with the thought
in mind that no physiological measures of neurotoxicity were taken, and that
neurotoxicity in these subjects was thus not confirmed.

Protection Against MDMA Neurotoxicity

An area o f particular interest to the present study is the finding that MDMA
neurotoxicity can be protected against. The compounds 6-nitroquipazine, paroxetine,
and the benzylpiperazines p-nitrobenzylpiperazine, p-chlorobenzylpiperazine, and 1piperonlypiperazine, are all potent serotonin uptake inhibitors and have been shown to
attenuate the 5-HT depletion associated with MDMA neurotoxicity (Hashimoto,
Maeda, & Goromaru, 1992a, b). Further, the 5-HT uptake inhibitors MDL 11,939,
citalopram and fluoxetine are some of the most frequently studied drugs that protect
against the neurotoxicity of MDMA (Schmidt, Black & Taylor, 1990; Sprouse,
Bradberry, Roth, & Aghajanian, 1989; OHeam, Battaglia, DeSouza, Kuhar, &
Molliver, 1988; Azimitia, Murphy, & Whitaker-Azimitia, 1990; Schmidt, 1987).
Interestingly, fluoxetine may provide this protection without affecting the
discriminable effects of MDMA (McCann & Ricaurte, 1993). Protection by the
noncompetitive N-methyl-D-aspartate calcium channel antagonist, MK-801, suggests
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that the toxicity of MDMA may depend, at least in part, on disturbances in the
homeostasis of the calcium channels of the 5-HT receptor population (Coloado,
Murray, & Green, 1993; Azimitia, Murphy, & Whitaker-Azimitia, 1990; Farfel,
Vosmer, Seiden, 1992).
Serotonergically active drugs are not the only compounds that protect against
MDMA neurotoxicity. The effects of MDMA neurotoxicity can be attenuated by the
interruption of monoamine synthesis by monofluoromethyl DOPA, the depletion of
vesicular monoamines via reserpine, or the inhibition of DA synthesis by AMPT or by
6-OHDA lesions in the substantia nigra (Schmidt, Black, & Taylor, 1990). This, plus

the findings that the administration of the DA antagonist haloperidol or the
monoamine oxidase inhibitor 1-deprenyl also protects agains MDMA neurotoxicity not
only demonstrates that DA appears to be involved in MDMA neurotoxicity, but that
the manipulation of the DA system may protect against it (Schmidt, Black & Taylor,
1990; Sprague & Nichols, 1995a, b).

The Behavioral Effects of MDMA Neurotoxicity

A great deal of research has obviously been performed on the physiological and
neurotoxic effects o f MDMA. Although some very salient behavioral effects of
MDMA exist, there is a comparative paucity of research on the behavioral
consequences of MDMA neurotoxicity. A few studies, however, have brought some
of the most notable behavioral effects of MDMA neurotoxicity to light.
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Although there is certainly no deficit in the reported physiological changes
involved in MDMA neurotoxicity, corollary changes in behavior appear to be few and
far between. Slikker, Holson, Ali, Kolta, Paule, Scallet, McMillan, Bailey, Hong, and
Scalzo (1989) noted no significant changes in maze-learning or reflexive behavior.
Ali, Newport, Scallet, Binienda, Ferguson, Bailey, Paule & Slikker (1993) noted no
observable behavior change in rhesus monkeys observed in their home cage after
neurotoxic dosing. Robinson, Castaneda, and Whishaw (1993) noted that rats after
neurotoxicity had a longer acquisition latency in negotiating a water maze, but no
changes in foraging or "skilled reaching". In the skilled reaching test, food acquisition
was contingent on the rats' ability to reach the food bin, which was placed a
considerable distance on the other end of an aperture. However, although no
neurotoxicity was found in pups that were prenatally exposed to a neurotoxic MDMA
regimen, St. Omer et al. (1991) noted that these young rats developed better olfactory
discrimination and that negative geotaxis (180° rotation within 60 s after being placed
facing down a 25° incline) was delayed in the female offspring.
Also of particular importance to the present paper, it has been established that
neurotoxicity attenuates the discriminative stimulus control exerted by MDMA.
Schechter (1991b) found that when para-chlorophenylananine (p-CPA), a competitive
TPH inhibitor was injected daily for three days (100 mg/kg, i.p.) in rats trained to
discriminate (±)-MDMA from saline, the discrimination of the training compound was
disrupted. Similarly, a neurotoxic dose of fenfluramine (4.0 mg/kg, i.p., bid x 4 days)
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was found to attenuate the discriminative stimulus control of (±)-MDMA in one study
(Baker & Makhay, 1996). Curiously, amphetamine, a drug that had heretofore only
substituted for MDMA on irregular occasions, substituted rather well for (±)-MDMA
after the rats had endured a neurotoxic dose regimen in the Baker and Makhay (1996)
study. Finally, Schechter (1991a) demonstrated that although a neurotoxic regimen of
(±)-MDMA did not affect the conditioned place preference engendered by (±)MDMA, discrimination of the drug had been strongly decremented.

The Purpose of the Present Study

Since the optical isomers of MDMA appear to be drastically distinct from each
other and the racemate, it was of particular interest to delineate the effects of

(±)-

MDMA-induced neurotoxicity on the discriminative stimulus properties of each isomer
individually. Further, although it is well established that the 5-HT reuptake inhibitor,
fluoxetine, protects against the neurochemical aspects of MDMA neurotoxicity, its
effects on the behavioral aspects of neurotoxicity, specifically the discriminative
stimulus control exerted by the isomers of MDMA, have yet to be established. Thus,
the present study was designed to provide such information by the administration of a
neurotoxic (±)-MDMA regimen, with or without concomitant fluoxetine injections, to
rats trained to discriminate either (+) or (-)-MDMA from saline in a two-lever drug
discrimination procedure.
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CHAPTER II

METHODS

Subjects

Thirty male Sprague-Dawley rats (Harlan Breeding Laboratories, Harlan, IN)
weighing 390-450 g at the beginning of the study were used. Animals were housed
individually in a temperature- and humidity-controlled colony (22-29°C and 39-50%,
respectively) maintained on a 12 h light-dark schedule (0700 h-1900 h light). Standard
laboratory rodent diet was available ad libitum. Access to water was restricted to
amounts obtained during training sessions, for 10-15 minutes following training and
test sessions, and for at least 24 h on weekends. Twenty-four rats were randomly
divided into two groups of 12 and each group was assigned to be trained to
discriminate (-)-MDMA or (+)-MDMA. Each group of 12 rats was further divided
into groups of six. Rats in each group in each isomeric condition received
concomitant injections either saline and (±)-MDMA (MDMA) or fluoxetine and (±)MDMA (FLX + MDMA) during the neurotoxic drug administration regimen. Thus,
four groups of six rats were formed, consisting of rats trained to discriminate (-)MDMA or (+)-MDMA that were exposed to MDMA or FLX + MDMA conditions.
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The remaining six subjects were maintained as drug and experimentally naive
controls for postmortem neurochemical analysis. Two of the 12 rats exposed to (-)MDMA died unexpectedly during discrimination training, and seven died during the
neurotoxic drug administration regimen, leaving three rats to complete the study in the
(-)-MDMA condition.

Apparatus

Training and testing were conducted in eight commercially available chambers
(Med-Associates standard operant chamber ENV-001), housed in sound- and lightattenuating shells, which provided ventilation and masking noise. Each chamber
contained a 28 V house light and dipper (0.1 ml) mounted equidistant between two
levers. A Zenith Z-320/SX microcomputer, located in an adjacent room, controlled
experimental events and data collection via interface and software (Med-Associates,
East Fairfield, VT).

Drugs

The drugs used in the present experiment were dissolved in 0.9% bacteriostatic
saline and administered s.c. in a volume of 1 ml/kg. The drugs and dose ranges were:
(+)-MDMA hydrochloride (0.375, 0.75, and 1.5 mg/kg), (-)-MDMA hydrochloride
(0.75, 1.0, 1.5, 2.0, 3.0, and 4.0 mg/kg), (±)-MDMA hydrochloride (10, 20 mg/kg)
and fluoxetine hydrochloride (5.0 mg/kg). MDMA and its stereoisomers were
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generously granted from the National Institute on Drug Abuse (NIDA, Providence,
RI) and fluoxetine was the charitable gift of Eli Lilly (Indianapolis, IN).

Behavioral Procedures

Training

Subjects were initially trained to discriminate (+)-MDMA (1.5 mg/kg, n = 12)
or (-)-MDMA (3.0 mg/kg, n =12) from saline in a two lever, water reinforced drug
discrimination task. Injections of drug or saline were administered 20 min prior to 20
min sessions which were run six days per week. Drug or saline was given randomly,
with the restriction that neither condition occur for more than two consecutive days.
Half of the animals were reinforced with water for responses on the left lever
following drug, and reinforced on the right lever following saline injections; conditions
were reversed in the remaining animals. The number of consecutive correct responses
required for reinforcement was gradually increased from 1 to 20 until all animals
maintained reliable rates of responding under an FR 20 schedule. Reinforcement was
conditional upon the completion of the FR on the correct lever (drug or saline);
responding on the incorrect lever was recorded and resulted in the resetting of the FR
20 schedule, but had no additional programmed consequences. To reduce olfactory
cues (c.f., Extance & Goudie, 1981), the levers were wiped with an isopropyl alcohol
solution before each session. Further, the order in which the animals received training
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was randomized. When animals attained a criterion of 80% correct prior to the
delivery of the first reinforcer on 8 out o f 10 consecutive sessions, testing began.

Dose Response Testing

Animals were administered substitution tests with several doses of the training
drug (0, 0.375, 0.75, or 1.5 mg/kg (+)-MDMA; 0, 0.75, 1.5, or 3.0 mg/kg (-)MDMA) which, were administered in place of the training drug. Test sessions
terminated without reinforcement following the completion of the 20 consecutive
responses on either lever of after 20 min had elapsed. Test sessions were conducted
once or twice per week in animals that maintained a minimum of 80% for at least two
consecutive training sessions (i.e., drug and saline) between tests. After all doses were
tested, sham neurotoxic dosing began.

Sham Injection Regimen

All subjects were administered two injections of vehicle twice daily (10 a.m.
and 10 p.m.) for four days. The rats were not trained or tested during this period, nor
for 9 days afterward. On the fourteenth day following the initial injection, half of the
rats were tested for stimulus generalization to the training dose and the other half were
exposed to a similar test using vehicle. The following day, the rats were tested again
with reversed conditions (i.e., the rats that were exposed to a saline substitution test
the previous day were tested for generalization to the training dose, and vice versa).
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The following day, the rats were exposed to training sessions until discrimination
criterion was met again, at which point the (±)-MDMA neurotoxic administration
began.
Rats trained to discriminate (-)-MDMA, however, failed to maintain
discrimination after this regimen and were retrained per the above procedure to
discriminate (-)-MDMA at a slightly higher dose (4.0 mg/kg). A dose response curve
was then reestablished as above using slightly different doses (0, 1.0, 2.0, and 4.0
mg/kg) and a second sham neurotoxic injection regimen was implemented, followed by
a second generalization test. Rats undergoing this second test were tested twice on
each condition (training dose and vehicle) in an alternated order similar to that
described above and the average of each condition was taken. After this testing
procedure, the rats were exposed to testing sessions again until the discrimination
criterion were met, at which point the neurotoxic regimen was implemented.

Neurotoxic Injection Regimen

Under this condition, rats were administered 20 mg/kg (±)-MDMA twice daily
for four days (c.f. Schechter, 1991) on a 12 h schedule (10 a.m. and 10p.m.). Half of
the rats in each isomeric condition were administered 5.0 mg/kg fluoxetine a few
seconds before each (±)-MDMA injection. Similar to the sham neurotoxic
administration procedure, the rats were not trained or tested during this time or for the
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next 9 days. They were then exposed to alternated saline/training drug substitution
tests and retrained until discrimination criterion is was met once more.
Initially, eight of the ten surviving rats in the (-)-MDMA condition were
administered the described neurotoxic dose. However, seven of these rats died by the
third injection. The single surviving rat completed this dosing regimen at a lower dose
of (±)-MDMA (10 mg/kg) and the remaining two were administered this lower dose
at each injection of the neurotoxic procedure. Consistent with the sham neurotoxic
procedure, these three rats were exposed to two alternated tests of saline/training drug
substitution tests each and the mean performance calculated for both testing
conditions. After this testing procedure, the rats were retrained until criterion was met
again.

Postmortem Neurochemical Assays

After the third discrimination criterion was met, the rats were given a seven
day drug holiday with food and water available ad libitum. On the eighth day after
criterion was met, the rats were sacrificed by decapitation via a commercially available
rat guillotine (Braintree Scientific, Braintree, MA). The brains were rapidly removed
and rinsed with ice-cold saline and placed in a chilled cutting block . The ventral
striatum as well as the prefrontal cortex were removed and placed in separate tubes
and frozen on dry ice. Samples were stored at -80°C until they were analyzed for
monoamine content at the facilities of Pharmacia & Upjohn (Kalamazoo, MI). The
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sections were then homogenized via a sonifier in a 500 ml buffer of a 10% solution of
EDTA, 5% glutathione, and 0.01 N PCA and centrifuged at 14,000 r.p.m for 14 min
at 4° C. The supemate was then drawn off and assayed by HPLC and electrochemical
detection.

Data Analysis

Percent drug lever responding was defined as the number of responses emitted
on the lever associated with the training drug, divided by the total number of responses
that occurred during a test session (X 100). Rate (responses per second) was the total
number of responses that occurred during a test, divided by the number of seconds
taken to complete the test. Data from animals that failed to complete 20 responses
during stimulus generalization tests were discarded. The criteria for complete
substitution were: (a) a mean of at least 80% drug-appropriate responding; and (b)
that this mean was significantly different from that of saline control tests.
Sessions to criterion (STC) was defined as the number of training sessions
required for a given subject to achieve criterion. STC was recorded at three points:
during initial training prior to the dose response testing (STC 1), during retraining after
the sham neurotoxic administration (STC 2 ), and during retraining after the neurotoxic
administration regimen (STC 3).
The effects of each substitution dose during the dose response analysis on each
of these measures were subjected to a one way repeated measures analysis of variance
(ANOVA). The effects of training drug/saline administration during generalization tests
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after sham or neurotoxic injections were analyzed via a 2-way ANOVA (Group x
Time). The Group factor refers to the regimen after which testing was performed
(sham injection regimen vs. neurotoxic injection regimen). Where appropriate,
Tukey’s multiple comparison test was used. Statistical analyses were performed using
GraphPad Prism software (Prism, San Diego, CA). Due to differential loss of subjects
in the (-)-MDMA condition, data analyses were not performed with data from that
isomer, save for the dose response analyses for each training drug. Data collected from
the postmortem neurochemical assays were subjected to one-way ANOVA analyses.
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CHAPTER III

RESULTS

(+)-MDMA
Dose Generalization

Figure 2 illustrates the dose dependent nature with which (+)-MDMA evoked
drug-appropriate lever responding in rats trained to discriminate 1.5 mg/kg (+)MDMA (F (3,33)= 18.53, p < 0.0001). Most notable is that the training dose
substituted completely for itself with a mean of 98.35% (SEM = 1.29) and saline
injections engendered little, if any, drug appropriate responding in the same rats (mean
= 0.725, SEM = 0.725). Doses of 0.375 and 0.75 mg/kg (+)-MDMA evoked %38.37
(SEM = 12.71) and 51.79% (SEM = 13.87) (+)-MDMA-appropriate responding,
respectively. Tukey's multiple comparison test indicated that the percent (+)-MDMA
lever responses engendered by saline was significantly lower than that of all other drug
doses (p < 0.05) and, conversely, drug-appropriate responding was much greater when
rats were injected with the training dose than with any other dose of (+)-MDMA (p <
0.05).
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Response rate also appeared to be affected by drug dose (F (3,33) = 2.93, p = 0.048),
which engendered mean rates o f 1.74 (Saline, SEM = 0.219), 1.22 (0.375 mg/kg,
SEM = 0.2), 1.32 (0.75 m/kg, SEM = 0.27), and 0.95 (1.5 mg/kg, SEM = 0.22)
responses per second. Tukey’s multiple comparison test, however, indicated that no
dose condition differed from any other in this measure.

Response Testing After Sham and Neurotoxic Injection Regimens

Figure 3 illustrates that, after the sham injection regimen, the training dose of
(+)-MDMA substituted for itself in the rats in the MDMA group (99.24%, SEM =
0.76) and those in the FLX + MDMA group (100.0%, SEM = 0.0). Conversely,
saline evoked very little, if any, (+)-MDMA responses from these rats in either
condition (MDMA: 2.78%, SEM = 2.78; FLX + MDMA : 9.42%, SEM = 4.27).
After the neurotoxic drug administration regimen, however, (+)-MDMA only
promoted criterion level drug-appropriate responding in rats that were concomitantly
administered fluoxetine with MDMA (100.0%, SEM = 0.0), as opposed to rats in the
MDMA group (44.99%, SEM = 19.74). Similarly, saline engendered more drug-like
responding in rats in the MDMA group (22.14%, SEM = 10.63) than in the FLX +
MDMA group (2.31%, SEM = 1.56).

A two way ANOVA of Group (MDMA vs.

FLX + MDMA) and Time (after sham injection regimen vs. after neurotoxic injection
regimen) was performed with the data from the training dose substitution tests. This
test indicated a significant interaction between the Group and Time factors (F(l,20) =
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8.4, p = 0.0089) and a significant main effect in both the Group (F(l,20) = 8.85, p =
0.0075) and the Time (F(l,20) = 8.4, p = 0.0089) factors. A similar analysis of the
data from the saline substitution tests indicate only a significant interaction between
the two factors (F(l,20) = 4.95, p = 0.038) and no significant main effect.
Figure 4 demonstrates the effects o f (±)-MDMA neurotoxicity and fluoxetine
on response rate. After the sham injection regimen, response rates engendered in the
rats in the MDMA group during saline and (+)-MDMA training dose substitution tests
were 1.77 (SEM = 0.45) and 0.89 (SEM = 0.196) responses per second, respectively.
Among the FLX + MDMA rats, saline substitution tests engendered 0.83 (SEM =
0.31) responses per second and (+)-MDMA training dose substitution tests
engendered 0.365 (SEM = 0.07) responses per second. After the neurotoxic injection
regimen, response rates during (+)-MDMA substitution tests were 0.89 (SEM = 0.23)
among rats in the MDMA condition and 0.997 (SEM = 0.2) in FLX + MDMA rats.
Response rates among rats in the MDMA and FLX + MDMA conditions during
training dose substitution tests were 1.25 (SEM = 0.282) and 0.895 (SEM = 0.122)
responses per second, respectively. Two way ANOVA's of the data obtained from
these tests indicated no significant interaction or main effect in this measure.

Sessions to Criterion (STO

The number of sessions to criterion (STC) prior to dose response testing (STC
1) was 31.39 (SEM = 1.47) among rats in the FLX + MDMA group and 33.33 (SEM
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= 1.33) among the rats in the MDMA group (Figure 5). Figure 5 also illustrates the
STC after chronic saline injections (STC 2) among MDMA (11.0, SEM = 1.0) and
FLX + MDMA (11.17, SEM = 1.17) rats, respectively. The STC after the neurotoxic
dosing regimen (STC 3) was 10.0 (SEM = 0) among the rats in the FLX + MDMA
condition and 17.0 (SEM = 4.82) in the subjects in the MDMA group. A two-way
ANOVA (Group vs. STC period) indicated no significant interaction and no main
effect for the Group factor. There was, however, a significant main effect in the STC
period factor (F(2,30) = 63.93, g < 0.0001). That is, STC's were lower at STC 2 and
STC 3 than at STC 1.

Postmortem Neurochemical Assays

A significant main effect was found in the 5-HT levels in the prefrontal cortex
areas of the subjects (F(2, 14) = 9.04, g = 0.003). Serotonin levels among rats in the
MDMA group were significantly lower than those in the rats in the Control (g < 0.01)
and the FLX + MDMA groups (g < 0.05). A similar main effect in rats in the 5-H3AA
levels of the subjects' prefrontal cortices (F(2, 24) = 11.88, g = 0.001). 5-HIAA
levels among the rats in both the MDMA (g < 0.05) and the FLX + MDMA (g < 0.05)
groups were significanlty lower than those found in the rats in the Control group. No
significant differences were found among any of the other neurotransmitters detected,
nor were any differences found among the striata of the rats in any condition (Figure
6).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

70

(+)-MDMA Trained Rats
40- r
001

SAL
■ IF L X
[ill

JZ,

x 30—
(01
V
VI
«<O 20 - u
u
001

T

■ fi

E
10 -

0-

-

I
STC 1

STC 2

STC 3

Training/Retraining period
Figure 5. Number of Sessions Prior to Criterion Preceding Dose Response Testing
(STC 1) After Sham Injection Regimen (STC 2) and After Neurotoxic (±)MDMA Administration (STC 3).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

71

Level* (ng/g tiuue)

Preftontel Cortex

SM

■CO N TRO L
□ F L X + MDMA ]
□M DM A

400
300
200
100

0

I'
5-HT

S-HIAA

DA

DOPAC

HVA

NE

Striatum
1400t __
ICONTROL
1200j □ F L X + MDMA]
□M DM A

*
ec
’eb
JS
«
>
v
-I

I

1000

800
600
400
200

0

DI
5-HT

cq

5-HIAA

DA

DOPAC

HVA

NE

¥Significantly different from Control (jj < 0.05).
** Significantly different from FLX + MDMA (£> < 0.05).

Figure 6 . Neurotransmitter and Major Metabolite Levels Detected in the Prefrontal
Cortices and Striata of Rats Under Control, FLX + MDMA, and MDMA
Conditions.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

72

(-)-MDMA

Dose Generalization With 3.0 mg/kg as a Training Dose

(-)-MDMA evoked drug-appropriate responding in a dose-dependent manner
in rats trained to discriminate 3.0 mg/kg (-)-MDMA (F(3, 36) = 6.97, p =
0.0008, Figure 7). O f primary interest is that the training dose substituted for itself
(81.82%, SEM = 12.197) and saline engendered little (-)-MDMA-like lever
responding (6.96%, SEM = 3.76). Substitution tests of doses of 0.75 and 1.5 mg/kg
(-)-MDMA resulted in 37.58% (SEM = 13.61) and 42.61% (SEM = 15.06) drug
appropriate responses, respectively. Tukey's multiple comparison test indicated that
the percent (-)-MDMA lever responses engendered by the training dose was
significantly greater than that evoked by saline (p < 0 .001 ).
Response rate, however, was unaffected by drug dose. The mean responses
per second for substitution tests of saline, 0.75, 1.5 and 3.0 mg/kg (-)-MDMA were
2.2 (SEM = 0.81), 1.14 (SEM = 0.22), 1.32 (SEM = 0.17), and 1.74 (SEM = 0.33)
responses per second, respectively (Figure 7).
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Dose Generalization With 4.0 mg/kg as a Training Dose

Figure 7 also illustrates the dose dependent nature with which (-)-MDMA
engendered drug appropriate responding in rats trained to discriminate 4.0 mg/kg (-)MDMA from saline (E(3,33) = 21.1, p < 0.0001). Consistent with the above
findings,the training dose substituted for itself (91.96%, SEM = 7.194) and saline
substitution resulted in less than criterion (-)-MDMA lever responses (8.33%, SEM =
8.33). Substitution tests with the intermediate doses of 1.0 and 2.0 mg/kg (-)- MDMA
yielded 17.5% (SEM= 11.14) and 60.94% (SEM= 13.48) (-)-MDMA appropriate
responding, respectively. Tukey's multiple comparison analysis indicated that
salineengendered significantly less drug appropriate responding than 2.0 and 4.0 mg/kg
(-)-MDMA (p < 0.001). Further, 1.0 mg/kg administration resulted in significantly
less drug appropriate responding than 2.0 mg/kg (p <0.01) and 4.0 mg/kg (p <
0 .001 ).

Response rate was reduced by increasing doses of (-)-MDMA (F(3,33) = 5.75,
p = 0.003), which engendered rates of 1.52 (saline, SEM = 0.262), 1.16 (1.0 mg/kg,
SEM = 0.202), 1.09 (2.0 mg/kg, SEM = 0.23), and 0.65 (4.0 mg/kg, SEM = 0.13)
responses per second, respectively. Tukey's multiple comparisons indicates that the
saline substitution test resulted in a significantly higher rate than did the training dose
(p<0.01).
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CHAPTER IV

CONCLUSIONS

The present results are consistent with previous finding (e.g., Baker et al.,
1997; Baker et al., 1995) that discriminative stimulus control can be established with
both isomers of MDMA and that this control provides a dose-dependent generalization
gradient. Further, the present study established the ability of (+)-MDMA to maintain
its discriminative stimulus properties over an extended period in which the subjects
were not exposed to training sessions. This training hiatus is inherent in the commonly
used neurotoxic drug administration procedure utilized herein, and thus any
conclusions based thereon can safely be disentangled from the procedural cessation in
training (c.fi, Schechter, 1991a). It is interesting to note that the present findings also
established that such discriminative control may be established via subcutaneous
injections at doses where it has, up to this point, primarily been achieved through a
route of more immediacy and invasiveness (i.e., intraperitoneal injections).
The neurochemical analysis of the prefrontal cortices of rats undergoing (±)MDMA neurotoxicity demonstrated a significant decrease in 5-HT and its major
metabolite, 5-HIAA, with little effect on the dopaminergic and noradrenergic systems
relative to control. This finding is consistent with previous research (e.g., Slikker et
al, 1988; Robinson, et. al., 1993) and supports the contention that (±)-MDMA
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neurotoxicity contributed to the disruption of the discriminative stimulus control of
(+)-MDMA. It is well-established that serotonergic depletion via neurotoxic
administration of 5-HT-mediated drugs (e.g., fenfluramine, p-chlorophenylalanine,
MDMA) deteriorates the discriminative control achieved with (±)-MDMA (Baker &
Makhay, 1996; Schechter, 1991a, b). The same has been found for other
serotonergically mediated drugs, including MDE and fenfluramine (Schechter, 1991b).
Thus, it appears that depletions within the serotonergic system significantly decrease
the ability of rats to discriminate centrally active drugs whose mechanism of action
primarily involves 5-HT activity. The present study extends this finding to include the
(+) isomer of this compound and further establishes that, although the neurotoxicity
may be permanent, discrimination of the training dose may be reestablished with little
or no loss of discriminative stimulus control (c.f.. Baker & Makhay, 1996).
Many factors may contribute to this phenomenon. It is possible that, since (+)MDMA is dopaminergically as well as serotonergically active (McKenna, Guan, &
Shulgin, 1991), that the discriminative control of this isomer may have been
reestablished with its dopaminergic properties playing a salient role. This is somewhat
supported by the findings of Baker and Makhay (1996), which noted that, after 5-HT
depletion by fenfluramine, the dopaminergically active drug, amphetamine, substituted
for (±)-MDMA. The substitution of amphetamine for MDMA in trained rats was,
until then, tentative at best. Further, Schechter (1997) noted that Fawn-Hooded rats—
an inbred strain of rats with an indogenous 5-HT storage deficit—showed no deficit in
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MDMA discrimination relative to Sprague-Dawley rats. It can also be argued,
however, that since the serotonergic depletion by MDMA neurotoxicity is incomplete,
the subjects may indeed be discriminating the drug on the basis of its serotonergic
properties, but at a functionally lower dose.
Of primary interest is that, though temporary with subsequent training, this
loss in the discriminative control by (+)-MDMA can be prevented. The postmortem
neurochemical analysis in the present study indicates that 5-HT levels were left
unaltered in the prefrontal cortices of rats given fluoxetine injections concomitant with
(±)-MDMA injections that would, normally, result in neurotoxicity in rats. By
providing concurrent administrations of fluoxetine, a drug commonly known to protect
against MDMA neurotoxicity (e.g., Schmidt, Black & Taylor, 1990), the
discriminative stimulus control exerted by (+)-MDMA can be preserved. This finding
provides heretofore unestablished information regarding the behavioral effects of
MDMA neurotoxicity—that it is possible that the behavioral deficits due to MDMA
neurotoxicity may be hindered along with the corollary biochemical events associated
with such neurotoxic treatment. The present finding is limited, however, by the
relative paucity of research regarding the behavioral effects of MDMA neurotoxicity
and even more so by the lack of behaviors that have been found to be thus affected.
It is unfortunate that the subjects that were trained to discriminate 3.0 mg/kg ()-MDMA from saline failed to maintain discrimination after the training recess in the
sham neurotoxic procedure. Since the discrimination of similar doses of this isomer
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through i.p. injections is well established, (e.g., Baker, et al., 1997) it is likely that, due
to the subcutaneous nature of the current drug administration route, the dose was not
high enough in this less potent isomer to maintain discriminative stimulus control after
an extended break in training. However, since no attempts have been previously made
to determine whether discriminative stimulus control by (-)-MDMA at that dose
administered by any route can be maintained over a period of no training, and that s.c.
injections of 3.0 mg/kg (-)-MDMA substituted perfectly in rats trained to discriminate
i.p. injections of the same dose of the drug from saline (Baker & Virden, unpublished
results), it is obvious that more research is necessary prior to making any conclusions
in that regard.
More's the pity that, after the requisite discrimination maintenance of a higher
dose of (-)-MDMA was established, the neurotoxic regimen of (±)-MDMA proved
toxic to most of the exposed rats, causing a significant differential depletion of subjects
in that condition, and rendering any analysis of the results obtained from them futile.
This near-tragic loss may be attributable to a number of causes. It is possible that
since the rats were exposed to considerably more injections of the training drug (by
47-50 injections) than their (+)-MDMA counterparts, due to retraining and the
reestablishing of a dose response curve at a higher training dose, that these rats may
have become sensitized to the potentially toxic effects of the higher doses of the
racemate. Further, it is also conceivable that, since the rats in the (-)-MDMA group
were somewhat older than the (+)-MDMA subjects (by 110-117 days), by the time the
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recieved the neurotoxic regimen, that the rats' relative age may have played an
important role in their deaths. It is more likely, however, that the unexpected deaths
of these subjects were the result of an unforeseen aberration in environmental factors.
It is known that high temperatures (25-30°) can facilitate the lethality of the dose of
(±)-MDMA employed in the present procedure (Gordon, Watkinson, O'Callaghan, &
Miller, 1991). Indeed, the range of room temperatures during the days of injection for
this group (25-29°C) was similar to that found to be fatally interactive with (±)MDMA by Gordon et al., (1991), and was considerably higher than the temperatures
during neurotoxic injection of the rats in the (+)-MDMA group (22-24°C), all of
which survived with no unexpected complications. However, these factors are
difficult to disentangle and, again, more research is necessary before any conclusions
can be safely made.
It can be argued that this relative paucity in research may be due to a lack of
sensitive means by which to detect functional MDMA neurotoxicity. Schechter
(1991a) demonstrated that the drug discrimination procedure may be an avenue
through which it may be quantified. Further, the present study has demonstrated that
this procedure may detect the preservation of behavioral functions against MDMA
neurotoxicity, thus facilitating further research in this field. In summary, the present
findings indicate that the discriminative stimulus control of (+)-MDMA as disrupted by
(±)-MDMA neurotoxicity can be established, regained, and protected against.
Although there is a present lack of research involving the behavioral effects of
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MDMA neurotoxicity, the present study underscores the need for such explorations,
and brings to light a potentially important tool with which it may be accomplished.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Appendix
Protocol Clearance From the Insittutional Animal
Care and Use Committee (IACUC)

81

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

82
WESTERN MICHIGAN UNIVERSITY
INVESTIGATOR IACUC CERTIFICATE
Title or Project: Discriminative Stimulus Effects of MDMA: Effects o f Fluoxetine on
Neurotoxicity______ ________________________________________________________ _
The information included in this IACUC application is accurate to the best of my knowledge. All
personnel listed recognize their responsibility in complying with university policies governing the
care and use of animals.
I declare that all experiments involving live animals will be performed under my supervision or
that of another qualified scientist. Technicians or students involved have been trained in proper
procedures in animal handling, administration of anesthetics, analgesics, and euthanasia to be used
in this project
If this project is funded by an extramural source, I certify that this application accurately reflects
all procedures involving laboratory animal subjects described in the proposal to the funding
agency noted above.
Any proposed revisions to or variations from the animal care and use data will be promptly
forwarded to the IACUC for approval.
Disapproved

Approved

_J^^Approved with the provisions
listed below

Provisions or Explanations:
. n
.. \
IrarCtfe. ^ ________________________________________________ -c * _____________
- L- Kv> A * siw l.o.i
ia.6
.-------------------------------------

iirperson

RECEIVED

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

83
Acceptance of Provisions

igator/Instmctor

76&Js i
Date

Approval
Approved IACUC Number

^ *?~ 06*

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

BIBLIOGRAPHY

Ali, S. F., Newport, G. D., Bailey, J. R., & Slikker, W. (1990). Oral administration
of MDMA produces selective serotonergic neurotoxicity in rodents and
nonhuman primates. SAAS Bulletin o f Biochemistry and Biotechnology, 3, 4853.
Ali, S. F., Newport, G. D., Scallet, A. C., Binienda, Z., Ferguson, S. A., Bailey, J. R.,
Paule, M. G., & Slikker, W. (1993). Oral administration of 3, 4methylenedioxymethamphetamine (MDMA) produces selective serotonergic
depletions in the nonhuman primate. Neurotoxicology and Teratology, 15, 9196.
Ali, S. F., Scallet, A. C., Newport, G. D., Lipe, G. W., Holson, R. R., & Slikker, W.
(1989). Persistent neurochemical and structural changes in rat brain after oral
administration of MDMA. Research Communications o f Substance Abuse, 10,
255-235.
Allen, R. P., McCann, U. D., & Ricaurte, G. A. (1993). Persistent effects of (+/-)3,
4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep.
Sleep, 16, 560-564.
Altar, C. A., Wesley, A. M., Liebman, J., Gerhard, S., Kim, H., Welsh, J. J., & Wood,
P. L. (1987). CGS10746B: An atypical antipsychotic candidate that
selectively decreases dopamine release at behaviorally effective doses. Life
Science, 39, 699-705.
American Medical News. (June 14, 1985). DEA to outlaw hallucinogenic "ecstasy”,
p. 18.
Anderson, G. M., Braun, G., Braun, U., Nichols, D. E., & Shulgin, A. T. (1978).
Absolute configuration and psychotomimetic activity. NIDA Research
Monograph Series, 22, 8-15.
Appel, J. B. & Cunningham, K. A. (1986). The use of drug discrimination procedures
to characterize hallucinogenic drug actions. Psychopharmacology Bulletin,
22, 959-969.

84

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

85

Azimitia, E. C., Murphy, R. B., & Whitaker-Azimitia, P. M. (1990). MDMA
(ecstasy) effects on cultured serotonergic neurons: Evidence for Ca^+dependent toxicity linked to release. Brain Research, 510, 97-103.
Baker, L. E., Broadbent, J., Michael, E. K., Matthews, P. K., Metosh, C. A.,
Saunders, R. B., West, W. B., & Appel, J. B. (1995). Assessment of the
discriminative stimulus effects o f the optical isomers of ecstasy (3, 4methylenedioxymethamphetamine; MDMA). Behavioural Pharmacology, 6,
263-275.
Baker, L. E. & Makhay, M. M. (1996). Effects of (+)-fenfluramine on 3, 4methylenedioxymethamphetamine (MDMA) discrimination in rats.
Pharmacology, Biochemistry, and Behavior, 53, 455-461.
Baker, L. E., Virden, T. B., Miller, M. E., & Sullivan, C. L. (1997). Time course
analysis of the discriminative stimulus effects of the optical isomers of 3, 4methylenedioxymethamphetamine (MDMA). Pharmacology, Biochemistry,
and Behavior, 58, 505-516.
Ballard, P. A., Tetrud, J. W., & Langston, J. W. (1985). Permanent human
parkinsonianism due to l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyrodine
(MPTP): Seven cases. Neurology, 35, 949-956.
Balster, R. L. & Schuster, C. R. A. (1973). A comparison of c/-amphetamine, 1amphetamine, and methamphetamine self-administration in rhesus monkeys.
Pharmacology, Biochemistry, and Behavior, I, 67-71.
Barnes, D. M. (1988). New data intensify the agony over ecstasy. Science, 239, 864866 .

Barrett, R. L., Wiley, J. L., Balster, R. L., & Martin, B. R. (1995). Pharmacological
specificity of D^-tetrahydrocannabinol discrimination in rats.
Psychopharmacology, 118, 419-424.
Barry, H. (1974). Classification of drugs according to their discriminable effects in
rats. Federal Processes, 33, 1814-1824.
Battaglia, G., Yeh, S., & DeSouza, E. B. (1988). MDMA-induced neurotoxicity of
degeneration and recovery of brain serotonin neurons. Pharmacology,
Biochemistry, and Behavior, 29, 269-274.
Beardsley, P. M., Balster, R. L., & Harris, L. S. (1986). Self-administration of
methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug and
Alcohol Dependence, 18, 149-157.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

86

Beck, J. & Morgan, P. (1986). Designer drug confusion: A focus on MDMA.
Journal o f Drug Education, 16, 287-302.
Beck, J. & Rosenbaum, M. (1994). Pursuit o f ecstasy: The MDMA experience.
Albany, NY: State University of New York Press.
Beebe, D. K. & Walley, E. (1991). Substance abuse: The designer drugs. American
Family Physician, 43, 1689-1698.
Bilsky, E. L„ Hui, Y„ Hubbel, C. L., & Reid, L. D. (1990).
Methylenedioxymethamphetamine's capacity to establish conditioned place
preference and modify intake of an alcoholic beverage. Pharmacology,
Biochemistry, and Behavior, 37, 633-638.
Boja, J. W. & Schechter, M. D. (1987). Behavioral effects of n-ethyl-3, 4methylenedioxyamphetamine (MDE; "Eve"). Pharmacology, Biochemistry,
and Behavior, 28, 153-156.
Braun, U., Shulgin, A. T., & Braun, G. (1980). Centrally active N-substituted
analogs of 3, 4-methylenedioxyphenylisopropylamine (3, 4methylenedioxyamphetamine). Journal o f Pharmacological Science, 69, 192195.
Broadbent, J., Appel, J. B., Michael, E. K., & Ricker, J. H. (1992). Discriminative
stimulus effects of the optical stereoisomers of MDA (3, 4methylenedioxyamphetamine). Behavioral, Pharmacology, 3, 443-454.
Broadbent, J., Michael, E. K., & Appel, J. B. (1989). Generalization of cocaine to
the isomers of 3, 4-methylenedioxyamphetamine and 3, 4methylenedioxymethamphetamine: Effects of training dose. Drug
Development Research, 16, 443-450.
Brodkin, J., Malyala, A., & Nash, J. F. (1993). Effect of acute monoamine depletion
on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity.
Pharmacology, Biochemistry, and Behavior, 45, 647-653.
Cadet, J. L., Ladenheim, B., Hirata, H., Rothman, R. B., Ali, S., Carlson, E„ Epstein,
C., & Moran, T. H. (1995). Superoxide radicals mediate the biochemical
effects of methylenedioxymethamphetamine (MDMA): Evidence from using
CuZn-superoxide dismutase transgenic mice. Synapse, 21, 169-176.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

87

Callahan, P. M. & Appel, J. B. (1988). Differences in the stimulus properties of 3, 4methylenedioxyampetamine and 3, 4-methylenedioxymethamphetamine in
animals trained to discriminate hallucinogens from saline. The Journal o f
Pharmacology and Experimental Therapeutics, 246, 866-870.
Callaway, C. W. & Cieyer, M A. (1992). Tolerance and cross-tolerance to the
activating effects of 3, 4-methylenedioxymethamphetamine and a 5hydroxytryptamineiB agonist. Journal o f Pharmacology and Experimental
Therapeutics, 263, 318-326.
Carroll, C. (1993). Drugs in modem society. (3rd ed.). IA: Brown & Benchmark.
Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1986). The discriminative
stimulus and subjective effects of ^-amphetamine, phenmetrazine and
fenfluramine in humans. Psychopharmacology, 89, 301-306.
Cho, A. K., Hiramatsu, M., Distefano E. W., Chang, A. S., & Jenden, D. J. (1990).
Stereochemical differences in the metabolism of 3, 4methylenedioxymethamphetamine in vivo and in vitro: A pharmacokinetic
analysis. Drug Metabolism and Disposition, 75,686-691.
Climko. R. P., Roehrich, H., Sweeney, D. R„ & Al-Razi, J. (1987). Ecstasy: A
review of MDMA and MDA. International Journal o f Psychiatric
Medicine, 16, 359-372.
Clineschmidt, B. V., Zacchel, A. G., Totaro, J. A., Pflueger, A., McGruffin, J. C., &
Wishoutsky, T. (1978). Fenfluramine and brain serotonin. Annual o f the New
York Academy o f Science, 305, 222.
Cohen, G. & Heikkila, R. E. (1974). The generation of hydrogen peroxide,
superoxide radical and hydroxyl radical by hyroxydopamine, dialuric acid, and
related cytotoxic agents. Journal o f Biological Chemistry, 249, 2447-2452.
Colado, M., Murray, T. K., & Green, A. R. (1993). 5-HT loss in rat brain following
3, 4-methylenedioxymethamphetamine (MDMA); p-chloramphetamine and
fenfluramine administration and effects of chlormethiazole and dizoclipine.
British Journal o f Pharmacology, 108, 583-589.
Colpaert, F.C. (1977). Drug induced cues and states: Some theoretical and
methodological inferences. In H. Lala (Ed.), Discriminative Stimulus
Properties o f Drugs, 5-21. NY: Plenum Press.
Colpaert, F. C. (1987). Drug discrimination in behavioral toxicology. Zentralblatt
feu r Bakteriologie, Mikrobiologie, und Hygiene, 185, 48-51.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

88

Colpaert F. C. (1988). Intrinsic activity and discriminative effects of drugs.
Psychopharmacology, 4, 154-160.
Commins, D. L., Vosmer, G., Virus, R. M., Woolverton, W. L., Schuster, C. R., &
Seiden, L. S. (1987). Biochemical and histological evidence that
methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat
brain. Journal o f Pharmacology and Experimental Therapeutics, 241, 338
-345.
Conger, J. J. (1951). The effects of alcohol on conflict behavior in the albino rat.
Studies in Alcohol, 12, 1-29.
Cox, R. H. & Maickel, R. P. (1972). Comparison of anorexigenic and behavioral
potency of some phenethylamines. Journal o f Pharmacology and
Experimental Therapeutics, 181, 1-9.
Culler, E., Coakely, J. D., Shurragar, P. S., & Ades, H. W. (1939). Differential
effects of curare upon higher and lower levels of the central nervous system.
American Journal o f Psychology, 52, 266-273.
Cunningham, K. A. & Appel, J. B. (1986). Possible 5-hydroxytryptaminei (5-HTj)
receptor involvement in the stimulus properties of l-(mtriflouromethylphenyI)piperazine (TFMPP). Journal o f Pharmacology and
Experimental Therapeutics, 237, 369-377.
Cunningham, K. A., Callahan, P. M., & Appel, J. B. (1987). Discriminative stimulus
properties of lisuride revisited. Involvement of dopamine D2 receptors.
Journal o f Pharmacology and Experimental Therapeutics, 241, 147-151.
Demirkiran, M., Jankovic, J., & Dean, J. M. (1996). Ecstasy intoxication: An
overlap between serotonin syndrome and neuroleptic malignant syndrome.
Clinical Neuropharmacology, 19, 157-164.
D'Mello, G. D. & Stolerman, I. P. (1977). Comparison of the discriminative stimulus
properties of cocaine and amphetamine in rats. British Journal o f
Pharmacoloy, 61, 415-422.
D'Mello, G. D. & Stolerman, I. P. (1978). Suppression of fixed-interval responding
by flavour-amphetamine pairings in rats. Pharmacology, Biochemistry, and
Behavior, 9, 395-398.
Dowling, C. G. (1985). Ecstasy. Life, Aug, 88-91

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

89

Dowling, G. P., McDonough, E. T ., & Bost, R. 0. (1987). "Eve" and "ecstasy". A
report on five deaths associated with the use of MDEA and MDMA. Journal
o f the American M edical Association, 257, 1615-1617.
Downing,! (1986). The psychological and physiological effects of MDMA on
normal volunteers. Journal o f Psychoactive Drugs, 75,335-340.
Dye, C. (1982). XTC: The chemical pursuit of pleasure. Drug Survival News, 10, 89.
Eisner, A. (1990). History of MDMA. In S. J. Peroutka (Ed.), Ecstasy: The
clinical, pharmacological, and neurotoxic effects o f the drug MDMA.
Norwell, MA: Kluwar Academic Press.
Evanko, D. (1991). Designer drugs: Treating the damage caused by basement
chemists. Postgraduate Medicine, 89, 67-70
Evans, S. M. & Johanson, C. E. (1986). Discriminative stimulus properties of (±)-3,
4-methylenedioxymethamphetamine and (+)-methylenedioxyamphetamine in
pigeons. Drug and Alcohol Dependence, 18, 159-164.
Evans, S. M., Zancy, J. P., & Johanson, C. E. (1990). Three-choice discrimination
among (+)-amphetamine, fenfluramine and saline in pigeons. Pharmacology,
Biochemistry, and Behavior, 35, 971-980.
Extance, K. & Goudie, A. J. (1981). Inter-animal olfactory cues in operant drug
discrimination procedures in rat. Psychopharmacology, 91, 67-73.
Farfel, G. M., Vosmer, G. L., & Seiden, L. S. (1992). The N-methyl-D-aspartate
antagonist MK-801 protects against serotonin depletions induced by
methamphetamine, 3, 4-methylenedioxymethamphetamine and pchloramphetamine. Brain Research, 595, 121-128.
Finnegan, K. T., Ricaurte, G. A., Ritchie, L. D., Irwin, I., Peroutka, S. J., & Langston,
J. W. (1988). Orally administered MDMA causes a long-term depletion of
serotonin in the rat brain. Brain Research, 447, 141-144.
Fitzgerald, R. L., Blanke, R. V., Narasimhachari, N., Glennon, R. A., & Rosencrans, J.
A. (June, 1987). Identification o f 3, 4-methylenedioxyamphetamine (MDA)
as a major urinary metabolite o f 3, 4-methylenedioxymethamphetamine
(MDMA). Presented at the CPDD meeting, Philadelphia, PA.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

90

France, C. P. & Woods, J. H. (1985). Opiate agonist-antagonist interactions:
Application o f a three-key discrimination procedure. Journal o f
Pharmacology and Experimental Therapeutics, 234, 81-89.
Frederick, D. L„ Ali, S., Slikker, W„ Gillam, M. P., Allen, R. R„ & Paule, M. G.
(1995). Behavioral and neurochemical effects of chronic
methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.
Neurotoxicology and Teratology, 11, 531-543.
Frederick, D. L., Gillam, M. P., Allen, R. R., & Paule, M. G. (1995). Acute effects of
methylenedioxymethamphetamine (MDMA) on several complex brain
functions in monkeys. Pharmacology, Biochemistry, and Behavior, 5/, 301307.
Fuller, R. W., Snoody, H. D., Snoody, A. M., Hemrick, S. K., Wong, D. T., &
Malloy, B. B. (1980). p-Iodoamphetamine as a serotonin depletor in rats.
Journal o f Pharmacology and Experimental Therapeutics, 212, 115-119.
Garattini, S., Barroni, E., Mennini, T, & Samanin, R. (1981). Differences and
similarities among anorectic agents. In Garattini, S. & Samanin, R. (Eds.),
Central Mechanisms o f Anorectic Dntgs. NY: Raven Press.
Gazzara, R. A., Takeda, H., Cho, A. K., & Howard, S. G. (1989) Inhibition of
dopamine release by methylenedioxymethamphetamine is mediated by
serotonin. European Journal o f Pharmacology, 168, 209-217.
Gershon, S. & Lang, W. J. (1962). A psychopharmacological study of some indole
alkaloids. Archives o f International Pharmacodynamics and Therapeutics,
135, 31.
Gertz, K. R. (1985). Hug drug alert: The agony of ecstasy. Harper's Bazaar, 263,
5-56.
Glennon. R. A. (1987a). Central serotonin receptors as targets for drug research.
Journal o f Medicine and Chemistry, 30, 1-12.
Glennon, R. A. (1987b). Psychoactive phenylisopropylamines. In H. Y. Meltzer
(Ed.), Psychopharmacology: The third generation o f progress. NY: Raven
Press.
Glennon, R. A. (1993). MDMA-like stimulus effects of a-ethyltryptamine and the aethyl homolog o f DOM. Pharmacology, Biochemistry, and Behavior, 46,
459-462.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

91

Glennon, R. A. & Higgs, R. (1992). Investigation of MDMA-related agents in rats
trained to discriminate MDMA from saline. Pharmacology, Biochemistry, and
Behavior, 43, 759-763.
Glennon. R. A. Higgs, R., Young, R., & Issa, H. (1992). Further studies on Nmethyl-l(3, 4-methylenedioxyphenyl)-2-aminopropane as a discriminative
stimulus: Antagonism by 5-hydroxytripamine3 antagonists. Pharmacology,
Biochemistry, and Behavior, 43, 1099-1106.
Glennon, R. A., Leibowitz, S. M., & Anderson, G. M. (1980). Serotonin receptor
affinities of psychoactive phenylalkylamine analogues. Journal o f Medicinal
Chemistry, 23, 294-299,
Glennon, R. A., Little, P. J., Rosencrans, J. A., & Yousif, M. (1987). The effects of
MDMA ("ecstasy") and its optical isomers on schedule-controlled responding
on mice. Pharmacology, Biochemistry, and Behavior, 26, 425-426.
Glennon, R. A., McKinley, J. D., & Young, R. Discriminative stimulus properties o f
the serotonin agonist l-(3-trifluouromethylphenyl )piperazine (TFMPP). Life
Science, 35, 1475-1480.
Glennon, R. A. & Meisenheimer, B. R. (1989). Stimulus effects on n-monoethyl-1(3, 4-methylenedioxyphenyl)-2-aminopropane (MDE) and n-hydroxy-l-(3, 4methylenedioxyphenyl)-2-aminopropane (MDA) in rats trained to discriminate
MDMA from saline. Pharmacology, Biochemistry, and Behavior, 33, 909912.
Glennon, R. A., Rosencrans, J. A., & Young, R. (1981). Behavioral properties of
psychoactive phenylisopropylamines in rats. European Journal o f
Pharmacology, 76, 353-360.
Glennon, R. A., Rosencrans, J. A., & Young, R. (1983). Drug-induced
discrimination: A description of the paradigm and a review of its application to
the study of hallucinogens. Medicinal Research Reviews, 3, 346-389.
Glennon, R. A., Titeler, M., Lyon, R. A., & Yousif, M. (1986). MDMA ("ecstasy"):
Drug discrimination and brain binding properties. Society fo r Neuroscience
Abstracts, 12, 919.
Glennon, R. A. & Young, R. (1984). Further investigation of the discriminative
stimulus properties of MDMA. Pharmacology, Biochemistry, and Behavior,
20, 501-505.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

92

Glennon, R. A., Young. R., Rosencrans, J. A., & Anderson, G. M. (1982).
Discriminative stimulus properties of MDA analogs. Biological Psychiatry,
17, 807-814
Glennon, R. A, Yousif, M., & Patrick, G. (1988). Stimulus properties of l-(3, 4methylenedioxyphenyI)-2-aminopropane (MDA) analogs. Pharmacology,
Biochemistry, and Behavior, 29, 443-449.
Glowinski, L. (1970). Effects of amphetamine on various aspects of catecholamine
metabolites in the central nervous system of the rat. In Costa, E. & Garattini,
S. (Eds.), Amphetamines and Related Compounds. NY: Raven Press.
Gold, L. H. & Koob, G. F. (1988). Methysergide potentiates the hyperactivity
produced by MDMA in rats. Pharmacology, Biochemistry, and Behavior, 29,
645-648.
Gold, L. H. & Koob, G. F. (1989). MDMA produces stimulant-like conditioned
locomotor activity. Psychopharmacology, 99,352-356.
Gold, L. H., Koob, G. F., & Geyer, M. A. (1988). Stimulant and hallucinogenic
behavioral profiles of 3, 4-methylenedioxymethamphetamine (MDMA) and Nethyl-3, 4-methylenedioxymethamphetamine (MDE) in rats. Journal o f
Pharmacology and Experimental Therapeutics, 247, 547-555.
Gordon, C. J., Watkinson, W. P., O'Callaghan, J. P., & Miller, D. (1991). Effects of
3, 4-methylenedioxymethamphetamine on autonomic thermoregulatory
responses of the rat. Pharmacology, Biochemistry, and Behavior, 38, 339344.
Gotesdam, K. G. & Gunner, L. M. (1972). Subjective effects of two anorexigenic
agents fenfluramine and AN 448 in amphetamine-dependent subjects. British
Journal o f the Addictions, 67, 39-44.
Goudie, A. J. (1977). Discriminative stimulus properties of fenfluramine in an
operant task: An analysis of its cue function. Psychopharmacology, 53, 97102.

Graham, D. G., Tiffany, S. M., Bell, W. R., & Gutnecht, W. F. (1978). Auto
oxidation versus covalent finding of quinones as the mechanism of dopamine,
6-hyroxydopamine, and related compounds towards c l300 neuroblastoma cells
in vitro. Molecular Pharmacology, 14, 644-653.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

93

Green, A. R., Cross, A. J., & Goodwin, G. M. (1995). Review o f the pharmacology
and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA
or "Ecstasy"). Psychopharmacology, 119, 247-260.
Greer, G. & Strassman, R. J. (1985). Information of "ecstasy". American Journal o f
Psychiatry, 142, 1391.
Griffith, J. D., Nutt, J. G., & Jasinski, D. R. (1975). A comparison of fenfluramine
and amphetamine in man. Clinical Pharmacology and Therapeutics, 18, 563570.
Grinspoon, L. & Bakalar, J. B. (1986). Can drugs be used to enhance the
psychotherapeutic process? American Journal o f Psychotherapy, XL, 393404.
Gudelsky, G. A., Yamamoto, B. K., & Nash, J. F. (1994). Potentiation of 3, 4methylenedioxymethamphetamine-induced dopamine release and serotonin
neurotoxicity by 5-HT2 receptor agonists,. European Journal o f
Pharmacology, 264, 325-330.
Ham’s, C. M., Wood, D. M., Lai, H., & Emmett-Oglesby, M. W. (1987). A method
to shorten the training phase of drug discrimination. Psychopharmacology, 93,
435-436.
Harris, R. T. & Balster, R. L. (1971). An analysis of the function of drugs in the
stimulus control of operant behavior. In T. Thompson and R. Pickens (Eds.),
Stimulus Properties o f Drugs, 111-132 NY: Appleton-Century-Crofts.
Hashimoto, K., Maeda, H., & Goromaru, T. (1992a). Effects of benzylpiperazine
derivatives on the neurotoxicity of 3, 4-methylenedioxymethamphetamine in rat
brain. Brain Research, 590, 341-344.
Hashimoto, K., Maeda, H., & Goromaru, T. (1992b). Antagonism of 3, 4methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1piperonylpiperazine. European Journal o f Pharmacology, 228, 171-174.
Henry, J. A., Jeffreys, K. J., & Dawling, S. (1992). Toxicity and deaths from 3, 4methylenedioxymethamphetamine ("ecstasy"). Lancet, 340, 384-387.
Hiramatsu, M. & Cho, A. K. (1990). Enantiomreic differences in the effects of 3, 4methylenedioxymethamphetamine on extracellular monoamines and
metabolites in the striatum of freely moving rats: An in vivo microdialysis
study. Neuropharmacology, 29, 269-275.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

94

Hiramatsu, M., Kumagi, Y., Unger, S. E., & Cho, A. K. (1990). Metabolism of
methylenedioxymethamphetamine and a quinone identified as its glutathion
adduct. Journal o f Pharmacology and Experimental Therapeutics, 254, 521527.
Hiramatsu, M., Nabeshima, T., Kameyama, T., Maeda, Y., & Cho, A. K. (1989). The
effect of optical isomers o f MDMA on stereotyped behavior in rats.
Pharmacology, Biochemistry, and Behavior, 33, 343-347.
Holohean, A. M., White, F. J., & Appel, J. B. (1982). Dopaminergic and
serotonergic mediation of the discriminable effects of ergot alkaloids.
European Journal o f Pharmacology, 81, 595-602.
Hrdina, P. D., Foy, B., Hepner, A., & Summers, R. J. (1990). Antidepressant binding
sites in brain: Autoradiographic comparison of [3H]paroxene and
[3H]imipramine localization and relationship to serotonin transporter. Journal
o f Pharmacology and Experimental Therapeutics, 252, 410-418.
Huang, X., Marona-Lewicka, D., & Nichols, D. E. (1992). pMethylthioamphetamine is a potent new non-neurotoxic serotonin-releasing
agent. European Journal o f Pharmacology, 229, 31-38.
Hubner, C. B., Bird M., Rassnick, S., & Kometsky, C. (1988). The threshold
lowering effects of MDMA (ecstasy) on brain-stimulation reward.
Psychopharmacology, 95, 49-51.
Hui, Q. L., Atrens, D. M., Christie, M. J., Jackson, D. M., & McGregor, I. S. (1993).
Comparison o f conditioned taste aversions produced by MDMA and damphetamine. Pharmacology, Biochemistry, and Behavior, 46, 153-156.
Insel, T. R., Battaglia, G., Johanssen, J. N., Massa, S., & DeSouza, E. B. (1989). 3,
4-methylenedioxymethamphetamine ("ecstasy") selectively destroys brain
serotonin terminals in rhesus monkeys. Journal o f Pharmacology and
Experimental Therapeutics, 249, 713-720.
Janssen. P. A. J. (1988). 5-HT2 receptor blockade to study serotonin-induced
pathology. Trends in Pharmacological Science, 4, 198-206.
Jarbe, T. U. (1986). State-dependent learning and drug discriminative control of
behaviour: An overview. Acta Neurologica Scandavia, 109, 37-59.
Jespersen, S. & Scheel-Kruger, J. (1973). Evidence for a difference in mechanism of
action between fenfluramine and amphetamine induced anorexia. Journal o f
Pharmacy Pharmacology, 25, 49-54.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

95

Johanson, C. E. & Uhlenhuth, E. H. (1982). Drug preferences in humans. Federal
Proceedings, 41, 228-233.
Johnson, M. P., Frescas, S. P., Oberlender, R., & Nichols, D. E. (1991). Synthesis
and pharmacological examination of l-(3-methoxy-4-methylphenyl)-2aminopropane and 5-methoxy-6-methyl-2-aminoindan: Similarities to 3, 4methylenedioxymethamphetamine (MDMA). Journal o f Medicinal Chemistry,
34, 1662.
Johnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986). Effects o f the enantiomers
of MDA, MDMA, and related analogues on [3H]dopamine release from
superfused rat brain slices. European Journal o f Pharmacology, 132, 269276.
Kamien, J. B., Bickel. W. K., Hughes, J. R., Higgens, S. T., & Smith, B. J. (1993).
Drug discrimination by humans compared to nonhumans: Current status and
future directions. Psychopharmacology, 117,259-270.
Kamien, J. B., Johanson, C. E., Schuster, C. R., & Woolverton, W. L. (1986). The
effects of (+)methylenedioxymethamphetamine and
(±)methylenedioxyamphetamine in monkeys trained to discriminate
(+)amphetamine from saline. Drug and Alcohol Dependence, 18, 139-147.
Kirsch, M. M. (1986). Designer Drugs. Minneapolis: CompCare Publications.
Kubena, R. K. & Barry, H. (1969). Two procedures for training differential
responses in alcohol and nondrug conditions. Journal o f Pharmacological
Science, 58, 99-101.
Lai, H. (1977). Discriminative stimulus properties o f drugs. NY: Plenum Press.
Lamb, R. J., & Griffiths, R. R. (1987). Self-injection of d, 13, 4methylenedioxymethamphetamine (MDMA) in the baboon.
Psychopharmacology, 91, 268-272.
Langston, J. W. (1985). MPTP neurotoxicity: An overview and characterization of
phases of toxicity. Life Science, 36, 20-206.
Leibowitz, S. F. (1978). Identification of catecholamine receptor mechanisms in the
perfomical lateral hypothalamus and their role in mediating amphetamine and
/-DOPA anorexia. In Garattini, S. & Samanin, R. (Eds.), Central
Mechanisms o f Anorectic Drugs. NY: Raven Press.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

96

LeSage, M., Clark, R., & Poling, A. (1993). MDMA and memory: The acute and
chronic effects of MDMA in pigeons performing under a delayed-matching-tosample procedure. Psychopharmacology, I JO, 327-332.
Li, A. A., Marek, G. J., Vosmer, G., & Seiden, L. S. (1989). Long-term central 5-HT
depletions resulting from repeated administration of MDMA enhances the
effects of single administration of MDMA on schedule controlled behavior of
rats. Pharmacology, Biochemistry, and Behavior, 33, 641-648.
Lin, H. Q., Atrens, D. M., Christie, M. J., Jackson, D. M., & McGregor, I. S. (1993).
Comparison of conditioned taste aversions produced by MDMA and damphetamine. Pharmacology, Biochemsitry, and Behavior, 46, 153-156.
Logan, B. J., Laverty, R., Sanderson, W. D., & Yee, Y. B. (1988). Differences
between rats and mice in MDMA (methylenedioxymethamphetamine)
neurotoxicity. European Journal o f Pharmacology, 152, 227-234.
Lyon, R. A., Glennon, R. A., & Titeler, M. (1986). 3, 4methylenedioxymethamphetamine (MDMA): Stereoselective interactions at
S-HTj and 5-HT2 receptors. Psychopharmacology, 88, 525-526.
Mack, R. B. (1985). A bit on the wilde side: MDMA abuse. North Carolina
Medical Journal, 46, 641-642.
Maisto, S. A, Galizio, M., & Conners, G. J. (1991). Drug use and misuse. Chicago:
Holt, Rinehart, and Winston.
Mansbach, R. S., Braff, D. L., & Geyer, M. A. (1989). Prepulse inhibition of the
acoustic startle response is disrupted by N-ethyl-3, 4methylenedioxyamphetamine (MDEA) in the rat. European Journal o f
Pharmacology,
Marona-Lewicka, D. & Nichols, D. E. (1994). Behavioral effects of the highly
selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan.
European Journal o f Pharmacology, 258, 1-13.
Martin, L. L. & Sanders-Bush, E. (1980). Comparison of the pharmacological
characteristics of 5-HT \ and 5-HT2 with those of serotonin autoreceptors
which modulate release. Naunyn Schmiedebergs Archives o f Pharmacology,
321, 165-170.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

McCann, U. D. & Ricaurte, G. A. (1993). Reinforcing subjective effects of (+/-) 3, 4methylenedioxymethamphetamine ("ecstasy") may be separable from its
neurotoxic actions: Clinical evidence. Journal o f Clinical Pharmacology, 13,
214-217.
McCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994). Serotonin
neurotoxicity after (+/-)-3, 4-methylenedioxymethamphetamine (MDMA;
ecstasy"): A controlled study in humans. Neuropsychopharmacology, 10,
129-38.
McDowell, D. M. & Kleber, H. D. (1994). MDMA: Its history and pharmacology.
Psychiatric Annals, 24, 127-130.
McElroy, J. F. & Feldman, R. S. (1984). Discriminative stimulus properties of
fenfluramine: Evidence for serotonergic involvement. Psychopharmacology,
83, 172-178.
McGuire, P. & Fahy, T. (1991). Chronic paranoid psychosis after misuse of MDMA
("ecstasy"). British Medical Journal, 302,691.
McKenna, D. J., Guan, X. M„ & Shulgin, A. T. (1991). 3, 4methylenedioxyamphetamine analogues exhibit differential effects on
synaptosomal release of ^H-dopamine and ^H-5-hydroxytripamine.
Pharmacology, Biochemistry, and Behavior, 38, 505-512.
McKenna, D. J. & Peroutka, S. J. (1990). The neurochemistry and neurotoxicity of
3, 4-methylenedioxymethamphetamine, "ecstasy". Journal o f Neurochemistry,
54, 14-22.
McKinley, J. D. & Glennon, R. A. (1986). TFMPP may produce stimulus effects via
a 5-HT [g mechanism. Pharmacology, Biochemistry, and Behavior, 24, 4347.
Michael, J. (1982). Distinguishing discriminative and motivational functions of
stimuli. Journal o f Experimental Analysis o f Behavior, 37, 149-155.
Miller, R. T., Lau, S. S., & Monks, T. J. (1997). 2, 5-bis-(glutathion-s-yl)-amethyldopamine, a putative metabolite of (+/-)-methylenedioxyamphetamine,
decreases brain serotonin concentrations. European Journal o f
Pharmacology, 323, 173-180.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Mokler, D. J., Robinson, S. E., & Rosencrans, J. A. (1987). (+) 3, 4Methylenedioxymethamphetamine (MDMA) produces long-term reductions in
brain 5-hydroxytryptamine in rats. European Journal o f Pharmacology, 138,
265-268.
Moore, K. A., Mozayani, A., Fierro, M. F., & Poklis, A. (1996). Distribution of 3, 4methylenedioxymethamphetamine (MDMA) and 3, 4methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning.
Forensic Science International, 83, 111-119.
Nader, M. A., Hoffman, S. M., & Barrett, J. E. (1989). Behavioral effects of(+)-3,
4-methylenedioxymethamphetamine (MDMA) in the pigeon: Interactions with
noradrenergic and serotonergic systems. Psychopharmacology, 98, 183-188.
Nash, J. F. (1990). Ketanserin pretreatment blocks MDMA-induced dopamine
release in the striatum as measured by in vivo microdialysis. Life Science, 47,
2401.
Nichols, D. E. (1986). Differences between the mechanism of action of MDMA,
MBDB and the classic hallucinogens. Identification of a new therapeutic class:
Entactogens. Journal o f Psychoactive Drugs, 18, 305-318.
Nichols, D. E., Johnson, M. P., & Oberlender, R. (1991). 5-Iodo-2-aminoindan, a
nonneurotoxic analogue of p-idoamphetamine. Pharmacology, Biochemistry,
and Behavior, 38, 135-139.
Nichols, D. E„ Lloyd, D. H., Hoffman, A. J., Nichols, M. B., Vim. G. K. W. (1982).
Effects of certain hallucinogenic amphetamine analogues on the release of
[•^H]serotonin from rat brain synaptosomes. Journal o f Medicine and
Chemistry, 25, 530-535
Nichols, D. E. & Oberlender, R. (1990). Structure-activity relationships ofMDMA
and related compounds: A new class of psychoactive drugs? Annals o f the
New York Academy o f Sciences, 600, 613-623.
Oberlender, R. & Nichols, D. E. (1988). Drug discrimination studies with MDMA
and amphetamine. Psychopharmacology, 95, 71-76.
O'Callaghan, J. P. & Miller, D. B. (1994). Neurotoxicity profiles of substituted
amphetamines in the C57BL/6J mouse. Journal o f Pharmacology and
Experimental Therapeutics, 270, 741-751.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

99

CHeam, E., Battaglia, G., DeSouza, E. B., & Kuhar, M. J. (1988).
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine
(MDMA) causes selective ablation of serotonergic axon terminals in forebrain:
Immunocytochemical evidence for neurotoxicity. Journal o f Neuroscience, 8,
2788-2803.
Overton, D. A. (1961). Discriminative behavior based on the presence or absence of
drug effects (abstract). American Psychologist, 16, 453-454.
Overton, D. A. (1964). State-dependent or 'dissociated' learning produced with
pentobarbital. Journal o f Comparative Physiological Psychology, 57, 3-12.
Overton, D. A. (1971). Discriminative control by drug states. In Thompson, T. &
Pickens, R. (Eds.), Stimulus Properties o f Drugs. NY: Appleton-CenturyCrofts.
Overton, D. A. (1982). Comparison of the degree of discriminability of various drugs
using the T-maze drug discrimination paradigm. Psychopharmacology, 76,
385-395.
Overton, D. A. (1984). State dependent learning and drug discriminations. In
Iversen, L. L., Iversen, S. D., and Snyder, S. H. (Eds.), Handbook o f
Psychopharmacology, vol 18. NY: Plenum Press.
Overton, D. A. (1988). Similarities and differences between behavioral control by
drug-produced stimuli and by sensory stimuli. Psychopharmacology Series, 4,
176-198.
Overton, D. A. (1991). A historical perspective on drug discrimination. NIDA
Research Monographs, 116, 5-24.
Paris, J. M. & Cunningham, K. A. (1991). Lack of serotonin neurotoxicity after
intraraphe microinjection of (+/-)-3, 4-methylenedioxymethamphetamine
(MDMA). Brain Research Bulletin, 28, 115-119.
Payne, W. A., Hahn, D. B., & Pinger, R. R. (1991). Drugs: Issuesfo r Today.
Chicago: Mosby Year Book.
Peroutka, S. J. (1987). Incidence of recreational use of 3, 4methylenedioxymethamphetamine (MDMA, "ecstasy1') on an undergraduate
campus. New England Journal o f Medicine, 317, 1542-1543.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

100

Peroutka, S. J., Newman, H., & Harris, H. (1988). Subjective effects of 3, 4methylenedioxymethamphetamine in recreational users.
Neuropsychopharmacology, I, 273-277.
Peroutka, S. J., Pascoe, N., Faull, K. F. (1987). Monoamine metabolites in the
cerebrospinal fluid of recreational users of 3, 4methylenedioxymethamphetamine MDMA; "ecstasy"). Research
Communications in Substances o f Abuse, 8, 125-138.
Picker, M. & Dykstra, L. A. (1987). Comparison of the discriminative stimulus
properties ofU50, 488 and morphine in pigeons. Journal o f Pharmacology
and Experimental Therapeutics, 243, 938-945.
Piercy, M. F., Lum, J. T., & Palmer, J. R. (1990). Effects of MDMA ('ecstasy') on
firing rates of serotonergic, dopaminergic, and noradrenergic neurons in the
rat. Brain Research, 526, 203-206.
Poland, R. E. (1990). Diminished corticotrophin and enhanced prolactin responses
to 8-hydroxy-2(di-n-propylamino) tetraline in
methylenedioxymethamphetamine pretreated rats. Neuropharmacology, 29,
1099-1101.
Randall, J. (1992). Ecstasy-fueled "rave" parties become dances of death for English
youths. Journal o f the American Medical Association, 268, 1505-1506.
Redhead, S. (1993) (Ed.). Rave off: Politics and deviance in contemporary youth
culture. Aldershot, England; Avebury.
Reidlinger, J. E. (1985). The scheduling of MDMA; A pharmacist's perspective.
Journal o f Psychoactive Drugs, 17, 167-171,
Ricaurte, G. A., DeLanney, L. E., Irwin, I., & Langston, J. W. (1988). Toxic effects
of MDMA on central serotonergic neurons in the primate: Importance of
route and frequency of drug administration. Brain Research, 446, 165-168.
Ricaurte, G. A., DeLanney, L. E., Wiener, S. G., Irwin, I., & Langston, J. W. (1988).
5-HydroxyindoIeacetic acid in cerebrospinal fluid reflects serotonergic damage
induced by 3, 4-methylenedioxymethamphetamine in CNS of non-human
primates. Brain Research, 474, 359-363.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

101

Ricaurte, G. A., Finnegan, K. T., Irwin, I., & Langston, J. W. (1990). Aminergic
metabolites in cerebrospinal fluid of humans previously exposed to MDMA:
Preliminary observations. Annals o f the New York Academy o f Science, 600,
699-710.
Ricaurte, G. A., Fomo, L. S., Wilson, M. A., DeLanney, L. E., Irwin, I., Molliver, M.
E., & Langston, J. W. (1988). (±)3, 4-Methylenedioxymethamphetamine
selectively damages central serotonergic neurons in nonhuman primates.
Journal o f the American Medical Association, 260, 51-55.
Ricaurte, G. A., Martello, A. L., Katz, J. L., & Martello, M. B. (1992). Lasting
effects of (+/-)-3, 4-methylenedioxymethamphetamine (MDMA) on central
serotonergic neurons in nonhuman primates: Neurochemical observations.
Journal o f Pharmacology and Experimental Therapeutics, 261, 616.
Ricaurte, G. A. & McCann, U. D. (1992). Neurotoxic amphetamine analogues:
effects in monkey and implication for human. Annals o f the New York
Academy o f Science, 648, 371-382.
Robinson, T. E., Castaneda, E., & Whishaw, I. Q. (1993). Effects of cortical
serotonin depletion induced by 3, 4-methylenedioxymethamphetamine
(MDMA) on behavior, before and after additional cholinergic blockade.
Neuropsychopharmacology, 8, 77-85.
Rolbein, S. (1985). In search of ecstasy. Boston Magazine, Nov, 210-213, 296-297.
Rosencrans, J. A. & Glennon, R. A. (1987). The effect of MDA and MDMA
("ecstasy") isomers in combination with pirenperone on operant responding in
mice. Pharmacology, Biochemistry, and Behavior, 28, 39-42.
Schechter, M. D. (1986a). Discriminative profile of MDMA. Pharmacology,
Biochemistry, and Behavior, 24, 1533-1537.
Schechter, M. D. (1986b). Serotonergic mediation of tetrahydro-b-carboline.
Pharmacology, Biochemistry, and Behavior, 24, 1209-1213.
Schechter, M. D. (1987). MDMA as a discriminative stimulus: Isomeric
comparisons. Pharmacology, Biochemistry, and Behavior, 27, 41-44.
Schechter, M. D. (1988a). Advantages and disadvantages of a rapid method to train
drug discrimination. Pharmacology, Biochemistry, and Behavior, 31, 239242.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

102

Schechter, M. D. (1988b). Use of TFMPP stimulus properties as a model of 5-HT 15
receptor activation. Pharmacology, Biochemistry, and Behavior, 31, 53-57.
Schechter, M. D. (1989). Serotonergic-dopaminergic mediation of 3, 4methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacology,
Biochemistry, & Behavior, 31, 817-824.
Schechter, M. D. (1990). Functional consequences of fenfluramine neurotoxicity.
Pharmacology, Biochemistry, and Behavior, 37, 623-626.
Schechter, M. D. (1991a). Effect of MDMA neurotoxicity upon its conditioned place
preference and discrimination. Pharmacology, Biochemistry, and Behavior,
38, 539-544.
Schechter, M. D. (1991b). Effect of serotonin depletion by p-chlorophenylananine
upon discriminative behaviors. General Pharmacology, 22, 889-893.
Schechter, M. D. (1997). MDMA-like stimulus effects of hallucinogens in male fawnhooded rats. Pharmacology, Biochemistry, and Behavior, 59, 265-270.
Schechter, M. D. & Boja, J. W. (1988). CGS 10746B is able to attenuate the effects
of amphetamine: Further evidence for dopaminergic mediation.
Pharmacology, Biochemistry, and Behavior, 30, 1089-1092.
Schechter, M. D. & Cooke, P. G. (1975). Dopaminergic mediation of the
interoceptive cue produced by ^/-amphetamine in the rat.
Psychopharmacologia, 42, 185-193.
Schechter, M. D. & Gordon, T. L. (1993). Comparison of the behavioral effects of
ibogaine from three sources: Mediation of discriminative activity. European
Journal o f Pharmacology, 249, 79-84.
Schmidt, C. J. (1987). Neurotoxicity of the psychedelic amphetamine,
methylenedioxymethamphetamine. Journal o f Pharmacology and
Experimental Therapeutics, 240, 1-7.
Schmidt, C. J., Black, C. K., & Taylor, V. L. (1990). Antagonism of the
neurotoxicity due to a single administration of
methylenedioxymethamphetamine. European Journal o f Pharmacology, 181,
59-70.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

103

Schmidt, C. J., Fayadel, G. M., Sullivan, C. K., & Taylor, V. L. (1992). 5-HT2
receptors exert a state-dependent regulation of dopaminergic function: Studies
with MDL 100,907 and the amphetamine analogue, 3, 4methylenedioxymethamphetamine. European Journal o f Pharmacology, 223,
65-74.
Schmidt, C. J. & Kehne, J. H. (1990). Neurotoxicity of MDMA: Neurochemical
effects. Annual o f the New York Academy o f Science, 600, 665-681.
Schmidt, C. J., Levin, J. A., & Lovenberg, W. (1987). In vitro and in vivo
neurochemical effects of methylenedioxymethamphetamine on striatal
monoaminergic systems in the rat brain. Biochemistry and Pharmacology, 36,
747-755.
Schmidt, C. J. & Taylor, V. L. (1988). Direct central effects of acute
methylenedioxymethamphetamine on serotonergic neurons. European Journal
o f Pharmacology, 156, 121-131.
Schmidt, C. J., Wu, L., Lovenberg, W. (1986). Methylenedioxymethamphetamine: a
potentially neurotoxic amphetamine analog. European Journal o f
Pharmacology, 124, 175-178.
Seiden, L. S. & Dykstra, L. A. (1977). Psychopharmacology: A biochemical and
behavioral approach. NY: Van Nostrand Rhinehold.
Series, H., Boeles, S., Dorkins, E., & Peveler, R. (1994). Psychiatric complications
of "ecstasy" use. Journal o f Psychopharmacology, 8, 60-61.
Seymour, R. (1986). MDMA. San Francisco: Haight Ashbury Publications.
Shulgin, A. & Nichols, D. E. (1978). Characterization of the new psychotomimetics.
In R. C. Stillman and R. E. Willette (Eds.), The Psychopharmacology o f
Hallucinogens. NY: Pergammon Press.
Slikker, W., Ali, S. F., Scallet, A. C., Frith, C. H., Newport, G. D., & Bailey, J. R.
(1988). Neurochemical and neurohistological alterations in the rat and monkey
produced by orally administered methylenedioxymethamphetamine (MDMA).
Toxicology and Applied Pharmacology, 94, 448-457.
Slikker, W„ Holson, R. R„ Ali, S. F., Kolta, M. G„ Paule, M. G„ Scallet, A. C„
McMillan, D. E., Bailey, J. R., Hong, J. S., & Scalzo, F. M. (1989).
Behavioral and neurochemical effects of orally administered MDMA in the
rodent and nonhuman primate. Neurotoxicology, 10, 529-542.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

104

Sprague, J. E. & Nichols, D. E. (1995a). Inhibition of MAO-B protects against
MDMA-induced neurotoxicity in the striatum. Psychopharmacology, 118,
357-359.
Sprague, J. E. & Nichols, D. E. (1995b). The monoamine oxidase-B inhibitor 1deprenyl protects against 3, 4-methylenedioxymethamphetamine-induced lipid
peroxidation and long term serotonergic deficits. Journal o f Pharmacology
and Experimental Therapeutics, 273, 667-673.
Sprouse, J. S., Bradberry, C. W., Roth, R. H., & Aghajanian, G. K. (1989). MDMA
(3, 4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe
neurons in brain slices via release of serotonin. European Journal o f
Pharmacology, 167, 375-383.
St. Omer, V. E. V., Ali, S. F., Holson, R. R., Durhart, H. M., Scalzo, F. M., &
Slikker, W. (1991). Behavioral and neurochemical effects of prenatal
methylenedioxymethamphetamine (MDMA) exposure in rats.
Neurotoxicology and Teratology, 13, 13-20.
Steele, T. D., McCann, U. D., & Ricaurte, G. A. (1994). 3, 4Methylenedioxymethamphetamine (MDMA "ecstasy"): Pharmacology and
toxicology in animals and in humans. Addiction, 89, 539-551.
Steele, T. D., Nichols, D. E., & Yim, G. K. W. (1987). Stereochemical effects of 3,
4-methylenedioxymethamphetamine (MDMA) and related amphetamine
derivatives on inhibition of uptake of [^H]-monoamines into synaptosomes
from different regions of rat brain. Biochemistry and Pharmacology, 36,
2297-2303.
Stolerman, I. P. (1998). The Drug Discrimination Biblioraphy. [On-line]
Available: http://www.arf.Org/DD_D_Base.html#introduction.
Stolerman, I. P., Baldy, R. E., & Shine, P. J. (1982). Drug discrimination: A
bibliography. In Colpaert, F. C. & Slangen, J. L. (Eds.), Drug
Discrimination: Applications in CNS Pharmacology. Amsterdam: Elsevier
Biomedical Press.
Stolerman, I. P. & D'Mello, G. D. (1981). Role of training conditions in
discrimination of central nervous system stimulants by rats.
Psychopharmacology, 73, 295-303.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

105

Stolerman, I. P. & Shine, P. J. (1985). Trends in drug discrimination research
analyzed with a cross-indexed bibliography, 1982-1983.
Psychopharmacology, 86, 1-11.
Stone, D. M., Hanson, G. R., & Gibb, J. W. (1987). Differences in the serotonergic
of methylenedioxymethamphetamine in rats. Neuropharmacology, 26, 16571661.
Stone, D. M., Johnson, M., Hanson, G. R., & Gibb, J. W. (1988). Role of
endogenous dopamine in the central serotonergic deficits induced by 3, 4methylenedioxymethamphetamine. Journal o f Pharmacology and
Experimental Therapeutics, 247, 79-87.
Stone, D. M., Stahl, D., Hanson, G., R. & Gibb, J. W. (1986). The effects of 3, 4methylenedioxymethamphetamine (MDMA) and 3, 4methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat
brain. European Journal o f Pharmacology, 128, 41-48.
Suarez, R. V. & Reimersma, R. (1985). "Ecstasy" and sudden cardiac death.
American Journalfo r Forensic Medicine and Pathology, 9, 339-341.
Thompson, D. M., Winsauer, P. J., & Mastropaolo, J. (1987). Effects of
phencyclidine, ketamine, and MDMA on complex operant behavior in
monkeys. Pharmacology, Biochemistry, and Behavior, 26, 401-405.
Toufexis, A. (1985). A crackdown on ecstasy. Time, June 10, 64.
Weissman, A. (1977). Drugs as discriminative stimuli. In Lai & Harbans (Eds.),
Discriminative Properties o f Drugs. NY: Plenum Press.
White, F. J. & Appel, J. B. (1981). A neuropharmacological analysis of the
discriminative stimulus properties of fenfluramine. Psychopharmacology, 73,
110-115.
White F. J. & Appel, J. B. (1982a). The role of dopamine and serotonin in the
discriminative stimulus properties of lisuride. Journal o f Pharmacology and
Experimental Therapeutics, 221, 421-427.
White, F. J. & Appel, J. B. (1982b). Training dose as a factor in LSD-saline
discrimination. Psychopharmacology, 76, 20-25.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

106

White, J. M. & Holtzman, S. G. (1983). Further characterization of the tree choice
morphine, cyclazone and saline discrimination paradigm: Opiods with agonist
and antagonist properties. Journal o f Pharmacology and Experimental
Therapeutics, 224, 95-99.
Wilson, M. A., Ricaurte, G. A., & Molliver, M. E. (1989). Distinct morphological
classes of serotonergic axons in primates exhibit differential vulnerability to the
psychotropic drug 3, 4-methylenedioxymethamphetamine. Neuroscience, 28,
121-137.
Wood, P. M., Lai, H., Yaden, S., & Emmett-Oglesby, M. W. (1985). One-way
generalization of clonidine to the discriminative stimulus produced by cocaine.
Pharmacology, Biochemistry, and Behavior, 23, 529-533.
Woods, J. H. & Tessel, R. E. (1974). Fenfluramine: Amphetamine congener that
fails to maintain drug-taking behavior in the rhesus monkey. Science, 185,
1067-1069.
Yamamoto, B. K. & Spanos, J. J. (1988). The acute effects of
methylenedioxymethamphetamine on dopamine release in the awake-behaving
rat. European Journal o f Pharmacology, 148, 195-203.
Young, R. & Glennon, R. A. (1986). Discriminative stimulus properties of
amphetamine and structurally related phenylalkylamines. Medical Research
Review, 6, 99-130.
Yousif, M. Y., Fitzgerald, R. L., Narasimhachari, N., Rosencrans, J. A., Blanke, R. V.,
& Glennon, R. A. (1990). Identification of metabolites of 3, 4methylenedioxymethamphetamine in rats. Drug and Alcohol Dependence, 26,
127-135.
Zancy, J. P., Virus, R. M., & Woolverton, W. L. (1990). Tolerance and cross
tolerance to 3, 4-methylenedioxymethamphetamine (MDMA),
methamphetamine, and methylenedioxyamphetamine. Pharmacology,
Biochemistry, and Behavior, 35, 637-642.
Ziance, R. L., Sipes, I. G., Kinnard, W. J., & Buckley, J. P. (1972). Central nervous
system effects of fenfluramine hydrochloride. Journal o f Pharmacology and
Experimental Therapeutics, 180, 110-117.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

IMAGE EVALUATION
TEST TARGET (Q A -3 )

✓

<y
ft
'v

/-

1.0

H
uZ

U i

fr

1*0

2.2

2.0

l.l
1.8

1.25

1.4

1.6

150mm

IIV H G E . I n c
1653 East Main Street
Rochester, NY 14609 USA
Phone: 716/482-0300
Fax: 716/288-5989

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

^y
/,

&

